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This dissertation is dedicated to the memory of my grandfather, Donald G. Henson, who
passed away on March 12, 2016. In my eyes, my grandfather was the epitome of all things
wonderful. His kindness, generosity and extraordinary work ethic have always inspired and will
continue to inspire me to lead a similar life. From him, I inherited the recognition that honor,
generosity and integrity, not wealth, power or egotism, are one’s legacy. I wish I could share this
achievement with him on Earth, but I know that his pride in me and love for me will be
celebrated in Heaven.
“There is joy in work.” – Don Henson
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ABSTRACT
A series of experiments studied the possible role for prolactin in the spring-time
recrudescence of ovarian activity in mares. The first experiment was based on cabergoline
administration to seasonally anovulatory mares to prevent the seasonal rise in endogenous
plasma prolactin to assess whether reduced prolactin altered onset of ovarian activity or first
ovulation. Although prolactin concentrations were reduced, basal prolactin concentrations
recovered from suppression by the time of the next injection (10 days later), even though lowdose sulpiride stimulation of prolactin was still suppressed by 85%. The subsequent experiment
tested whether season affected the duration and degree of suppression produced by a standard
dose of cabergoline. Mares were administered cabergoline at 1.5 mg/500 kg body weight in
March, June, September, and December. Duration of suppression was affected little by month of
assessment. Follow-up assessments with either low dose sulpiride (July) or thyrotropin releasing
hormone (October) challenges after administration of 5 mg cabergoline indicated that basal
prolactin concentrations always rebounded earlier than secretagogue-induced secretion. The third
experiment studied possible physical and hormonal characteristics of seasonally anovulatory
mares that might affect their response to a combined estradiol and sulpiride treatment for
inducing ovulation in winter. All mares received 50 mg of estradiol cypionate (ECP) followed by
3 g of sulpiride. Factors that were commonly associated with early-induced ovulation were:
adequate body condition, elevated plasma concentrations of leptin and insulin, and a greater LH
response to secretagogue prior to the start of the experiment. The final experiment studied the
hormonal production aspects of the first pre-ovulatory follicle of the breeding season in
seasonally anovulatory mares treated with ECP followed by injections of sulpiride 5 and 12 days
later, or ECP plus vehicle (controls), beginning in January. Date to first 35-mm follicle was
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advanced in sulpiride-treated mares. It was concluded that early-induced follicles are equally as
competent in terms of steroid production and ability to respond to circulating LH as preovulatory follicles occurring naturally in spring. These experiments support the model in which
an increase in circulating prolactin during winter can hasten follicular growth and advance the
date to first ovulation in most mares.
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CHAPTER 1: INTRODUCTION
An industry-imposed birthday of January 1 for most registered horse breeds has created
an incentive for horse owners and breeders to produce foals as early in the year as possible.
However, this becomes difficult due to the mare’s long gestation period and the seasonal nature
of the mare’s reproductive cycle. Mares in Louisiana typically enter a period of reproductive
inactivity, known as seasonal anestrus, in late October and do not return to cyclicity until early
April. Therefore, advancing the first ovulation of the season is desirable in order for breeders to
produce maximally competitive foals, i.e., born close to the January 1st birthdate, and has led to
years of study of spring transition in mares and numerous attempts to develop pharmacological
therapies for inducing early cyclicity.
Much effort is invested yearly in the effort to manipulate the mare’s reproductive cycle so
she ovulates in mid-February. The common method currently used in the field to induce early
cyclicity is artificial lighting. This has proven to be labor intensive and cost prohibitive for most
farms. Of the pharmacological therapies used tested to date, the most promising is the use of
prolactin (a pituitary hormone) or dopamine antagonists such as sulpiride or domperidone that
stimulate prolactin. Elevated prolactin during seasonal anestrus stimulates follicular growth and
hastens ovulation in most, but not all, mares. It is unclear how prolactin induces early ovulation,
but it is suspected that prolactin acts directly on the ovary.
Ten years of experimentation at Louisiana State University has revealed success rates
(percentage of mares ovulating early) ranging from 50 – 90% in mares treated with a
combination of estrogen and either domperidone, or sulpiride. The failure of all mares (100%) to
respond to treatment led to the current research projects, which were designed to identify an
obligatory role for prolactin during vernal transition and assess factors that might affect whether
or not a mare responds to stimulated prolactin with early ovulation.
1

An understanding of the ovarian changes that occur in the presence of prolactin will
allow researchers to identify cause-and-effect relationships between prolactin and ovarian
function. This knowledge could help generate new or perfect protocols to induce early cyclicity
in more mares. This could allow for enhanced breeding practices such as initiating cyclicity in
embryo donor and recipient mares, obtaining oocytes earlier for artificial reproductive
technologies or for natural breeding programs that wish to cycle mares earlier in the year.
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CHAPTER 2: REVIEW OF LITERATURE
2.1 Overview
General aspects of mare reproductive physiology have been extensively reviewed in my
master’s thesis [2.1], and are not repeated here for the sake of brevity. Details regarding ovarian
anatomy, cyclicity, seasonality of reproduction, and the role of prolactin in reproduction are also
covered in that document, as well as in the review article by Thompson and Oberhaus [2.2]. The
aim of this literature review is to address the most recent information regarding the use of
estrogen plus dopaminergic antagonists to hasten the date to first ovulation in seasonally
anovulatory mares, to detail the role of dopamine in reproduction in mares, and to evaluate a role
for prolactin in ovarian function in the horse.
A detailed account of the effects of prolactin and dopamine antagonists on ovarian
activity in seasonally anovulatory mares, and on hair growth and shedding can be found in the
review by Thompson and Oberhaus [2.2]. To summarize, several decades worth of research has
focused on using dopamine antagonists, particularly sulpiride, to stimulate prolactin in an effort
to hasten the vernal transition in mares. Given that the seasonal pattern of prolactin secretion
(low during winter vs. high during summer [2.3-2.5]) parallels seasonal reproduction in mares,
researchers hypothesized that stimulating prolactin at a time when it is naturally low would
return mares to reproductive cyclicity.
2.2 Use of Estradiol and Anti-dopaminergic Compounds
Anti-dopaminergic agents such as sulpiride and domperidone release the
adenohypophysis from hypothalamic dopaminergic suppression by blocking dopamine receptors
on pituitary lactotropes, thus stimulating prolactin release [2.6]. Kelley et al. [2.7] demonstrated
a greater prolactin response to sulpiride and thyrotropin releasing hormone (TRH) in mares pre-

3

treated with estradiol benzoate compared to mares receiving sulpiride alone. Treatment with
estradiol benzoate also increased plasma luteinizing hormone (LH) concentrations, which,
coupled with increased prolactin secretion, hastened the date to first ovulation in treated mares
[2.7]. Estradiol is a known stimulator of prolactin synthesis in pituitary lactotropes in many
species [2.8-2.10]. Thompson et al. [2.11] demonstrated a marked increase in pituitary content of
prolactin in pony mares treated with estradiol, suggesting a direct influence of estradiol on
prolactin synthesis.
Thompson et al. [2.12] determined that, in geldings, one injection of estradiol cypionate
(ECP) provided prolactin responses similar to those after several injections of estradiol benzoate
(same as those used by Kelley et al. [2.7]). Given the similar response, one injection of ECP was
chosen for further experimentation. Mitcham et al. [2.13, 2.14] compared prolactin and ovarian
responses in mares receiving ECP (50 or 100 mg) combined with domperidone (1.5 g) either 1,
6, or 11 days after ECP treatment. Success, as defined by ovulation within 28 days of treatment,
was similar in mares receiving either 50 or 100 mg of ECP, but was greater in mares receiving
domperidone 1 day later vs. 6 days or 11 days later. No effect of ECP dosage on circulating
prolactin was observed; however, prolactin in mares receiving domperidone 1 day later tended to
be higher when compared to days 6 and 11, although prolactin was stimulated at these times as
well. Mitcham et al. [2.13] also compared domperidone (1.5 g in biodegradable microparticles,
i.m.) with varying doses (0.75 and 1.5 g, i.m.) of a new, non-particle formulation of sulpiride in
ECP treated mares. Treatment with domperidone took place 1 day after treatment with 100 mg
ECP; treatment with sulpiride took place 1, 6 and 11 days post treatment with 100 mg ECP. The
prolactin response was similar in mares treated with either 0.75 g or 1.5 g sulpiride formula.
Mares that received domperidone or 0.75 g sulpiride did not ovulate earlier compared to
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controls; however, of the mares treated with the higher dose of sulpiride (1.5 g), 7 of the 9
ovulated earlier relative to controls. Although domperidone did stimulate prolactin, the response
tended to be lower than mares treated with sulpiride. Given the better prolactin response, as well
as its commercial availability, sulpiride has been chosen as the dopamine antagonist of choice for
subsequent studies conducted at Louisiana State University. Previous results have shown that
the effect of sulpiride on prolactin secretion is quick but not as long lasting as domperidone.
Therefore, either repeated injections of sulpiride are needed or development of a long acting
vehicle is necessary.
The ovarian results, albeit variable, have been mostly favorable. Kelley et al. [2.7]
reported a success rate (percentage of mares ovulating within a specified period of time) of 89%;
Mitcham [2.15] reported on multiple experiments, with the lowest success rate being 50%. In all
studies, mares not responding initially to the treatment regimen basically had ovulation dates
similar to mares not treated with a dopamine antagonist. It is this failure of a given mare to
respond with ovarian activity that has raised the question as to what factors may be involved in
her lack of response, or conversely, what factors contribute to the positive responses in mares
that do in fact respond to treatment with estrogen and a dopaminergic antagonist.
2.3 Role of Dopamine in Reproduction
The hypothalamic-pituitary axis is regarded as the control center regulating all
reproductive events, including puberty, estrous cyclicity, ovulation, and seasonal reproduction.
This involves input from both intrinsic and extrinsic factors to the hypothalamus which, in turn,
releases or inhibits release of gonadotropin releasing hormone (GnRH) accordingly. However, a
substantial amount of research has shown that the mammalian ovary receives direct neural inputs
via sympathetic nerves in addition to its hormonal inputs via the circulatory system [2.16-2.19].
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For example, denervation of the rat ovary results in delayed puberty, minimal follicular growth
and reduced estradiol secretion [2.20-2.21]. In the mare, dopaminergic and adrenergic nerves
have been observed in the uterus and cervix [2.22]. Moreover, Welsh [2.23] detected
catecholamingeric neurons in whole ovaries from anestrous and summer cycling mares.
Antibodies to tyrosine hydroxylase (TH) or dopamine-hydroxylase (DH), enzymes involved
in conversion of tyrosine to dopamine and dopamine to norepinephrine, respectively, were used
to immunolocalize neurons. Positive immunoreactive signals were present for TH and/or D
in all ovaries. The majority of neurons were positive for TH but not D, suggesting those
neurons were dopaminergic. In addition, King et al. [2.24] immunolocalized dopamine receptors
in both equine granulosa/theca cells as well as in the corpus luteum. Furthermore, ovarian cortex
as well as luteal tissue expressed D1 and D2 receptor messenger RNA (mRNA); a lower level of
expression was detected in the theca and granulosa layers of the follicle [2.24, 2.25]. Local
release and potential action of dopamine is evident at the level of the ovary; however, its
mechanism of action in cyclicity has yet to be determined in the mare.
Involvement of catecholamines, particularly dopamine, in reproduction has been
investigated in a number of species. Dopamine and dopamine-like compounds appear to have
anti-gonadal effects in teleost fish [2.26, 2.27], sheep [2.28, 2.29], and cows [2.30, 2.31].
Dopamine agonists have also been studied as a treatment to prevent progression of ovarian
hyperstimulation syndrome in women receiving fertility treatments [2.32, 2.33] as well as to treat
infertility associated with hyperprolactinemia [2.34].
Dopamine-like compounds, such as the ergot alkaloids found in endophyte infected
fescue grass, have well-documented deleterious effects on lactation and parturition in mares.
Mares grazing endophyte infected fescue during the last 60 days of gestation experience
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agalactia, prolonged gestation, hypertrophic and/or retained placental tissues, increased
occurrence of dystocia and still birth [2.35, 2.36]. The role of dopamine and dopamine-like
compounds in other aspects of mare reproduction such as estrous cyclicity have not been clearly
described.
Bennett-Wimbush et al. [2.37] treated three groups of seasonally anestrous pony mares
with perphenazine (dopamine antagonist) twice daily, bromocriptine (dopamine agonist) daily, or
vehicle from January 20 until ovulation. Perphenazine advanced the first ovulation by 30 days
compared to controls, while bromocriptine had no effect on time to first ovulation but did appear
to delay growth of preovulatory sized follicles. Similarly, Bass [2.38] administered a long acting
dopamine agonist, cabergoline, orally during the natural breeding season, which suppressed
prolactin concentrations but had little to no effect on ovulation or luteal progesterone production.
Interestingly, both Bennett-Wimbush et al. [2.37] and Bass [2.38] reported erratic and prolonged
estrous behavior in mares treated with dopamine agonists both during the non-breeding and
breeding seasons. While circulating prolactin concentrations were suppressed in both studies,
neither daily bromocriptine nor oral cabergoline were able to completely suppress prolactin for
any length of time.
2.4 Regulation of Prolactin by Dopamine
Unlike most other adenohypophyseal hormones, which rely on hypothalamic releasing
factors for secretion, prolactin secretion by lactotropes in the adenohypophysis is regulated
through tonic inhibition by hypothalamic dopamine [2.39]. Axons from dopaminergic neurons
terminate in the median eminence of the adenohypophysis, release dopamine into the
hypophysial portal system where it reaches the adenohypophysis by way of long portal vessels
and binds to dopamine receptors on the plasma membrane of lactotropes [2.40]. Five distinct
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dopamine receptors (D1 through D5) have been identified and can be grouped into two
subgroups: D1-like, which includes D1 and D5 receptors, and D2-like, which includes D2, D3
and D4 receptors [2.40].
Receptor variants D1 and D2 are expressed at higher levels and are more selective for
agonists and antagonists. It is through D2 receptors that dopamine primarily regulates prolactin
secretion [2.41]. Activation of D2 receptors on lactotropes results in both immediate changes in
membrane permeability, which prevents release of prolactin from secretory granules, as well as
gradual changes in cell machinery, such as inhibition of adenyl cyclase, decrease in inositol
phosphates and eventual decrease in prolactin gene expression [2.40]. Given the heterogeneous
nature of lactotropes [2.42-2.45], it is unclear whether these events occur in all cell types in the
same manner and at the same rate.
2.5 Subpopulations of Lactotropes
The ultrastructure of pituitary lactotropes has been described in several species [2.422.49]. Nogami et al. [2.46] reported four morphologically different lactotrope populations in the
male rat pituitary which differed based on the size of the cell as well as the size of secretory
granules. In most species studied, the majority of prolactin secreting cells were described as large
and containing large, dense secretory granules [2.47-2.49]; however, others have also reported
the findings of smaller prolactin-secreting cells which contained smaller granules [2.50, 2.51].
Few studies have determined differential secretory activity of these different cell types.
Christian et al. [2.51] described three morphological subtypes (Type I, II and III) of
prolactin-secreting cells in the rat pituitary. By examining exocytosis of prolactin granules, it
appeared all three types were inhibited by dopamine, but only Type II and Type III lactotropes
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were stimulated with TRH or vasoactive intestinal peptide (VIP), another known prolactin
secretogogue.
Rahmanian et al. [2.45] described morphological differences in two types of lactotropes
within the equine pituitary, Type I and II. Type I lactotropes were generally larger with large,
dense secretory granules, much like those observed in other species, and were indistinguishable
from the cells that contained both growth hormone and prolactin, the mammosomatotropes. Type
II lactotropes were generally smaller than Type I with smaller secretory granules. Both cell types
stained positive for prolactin; however, it is not known if both cell types secrete prolactin
similarly in response to secretagogues or inhibitors [2.45].
2.6 Cabergoline
In humans, the dopaminergic agonist pergolide was previously chosen for its long
duration of prolactin suppression (48 hr after a single 50 µg dose) [2.52] until the advent of
cabergoline. Cabergoline has been shown to be an even more potent and long acting
dopaminergic agonist with a single dose of 200 µg lasting 96 hr and 600 µg lasting 168 hr [2.53].
Recently, Hebert et al. [2.54] reported complete suppression of plasma prolactin concentrations
in mares and geldings with 5 mg of cabergoline in a slow releasing vehicle injected
intramuscularly. Even when challenged with a low dose of sulpiride 10 days after cabergoline
injection, prolactin remained suppressed. Magnitude and duration of suppression were
considerably greater in cabergoline treated horses compared to pergolide treated horses [2.54].
Additionally, Arana Valencia et al. [2.55] administered a total of 7 cabergoline injections 10
days apart and demonstrated no incidences of refractoriness to cabergoline in mares challenged
with sulpiride (one day before the next cabergoline injection) or side effects to the cabergoline
compound.
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2.7 Role of Prolactin in Regulation of Ovarian Gene Expression
Aside from its well-documented effects on lactation, prolactin has gained considerable
recognition as a hormone that supports other reproductive processes such as ovulation, formation
and maintenance of the corpus luteum (CL), and implantation. Prolactin has also been
demonstrated to be a permissive hormone which facilitates apoptosis and regression of the CL in
cycling rats [2.56, 2.57].
In regards to changes in ovarian gene expression in response to prolactin, most studies
have been conducted using the rat as a model. In rats, prolactin appears to be obligatory for
proper CL formation and maintenance [2.58, 2.59]. More specifically, it has been suggested that
prolactin is responsible for inducing functional LH receptors on granulosa cells and CL of rats as
well as sustaining progesterone secretion from the CL. In rat granulosa cells, prolactin has been
shown to sustain concentrations of LH receptors, but not without first being induced by FSH
[2.60]. Similar to these findings are the reports of Richards and Williams [2.61] and Holt et al.
[2.62] who observed an enhancive effect of prolactin on LH receptor content and progesterone
production, but not a direct effect of prolactin alone. Conversely, Bjurulf et al. [2.63] observed a
ten-fold increase in LH receptor messenger mRNA in luteal cells of prolactin-treated rats as well
as an increase in circulating progesterone concentrations when compared to controls. This effect
of prolactin on LH receptors and receptor mRNA in females is directly analogous to the
complete requirement for prolactin for spermatogenesis in the male hamster [2.64, 2.65], which
was shown to be mediated by prolactin’s necessity for LH receptors on hamster Leydig cells
[2.66].
One of the greatest arguments for a role for prolactin in ovarian function is the
aberrations observed in null mutant prolactin receptor mice: they display multiple reproductive
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defects including infertility, low ovulation rates, decreased fertilization rates and a markedly
reduced number of primary follicles [2.67]. Binart et al. [2.68] also observed reproductive
deficiencies in prolactin receptor knockout mice such as failure of the CL to produce
progesterone and failure of embryo implantation which was rescued by progesterone
administration. Grosdemouge et al. [2.69] failed to observe any differences in length of estrous
cycle, ovulation rates or ovarian response to gonadotropins in null mutant prolactin receptor
mice; however, they did observe irregularities in corpus luteum morphology such as highly
disorganized cells, early regression and extremely low vascularization, which they determined
led to luteal insufficiency. Furthermore, a marked decrease in LH receptor mRNA was detected
in null mutant mice. These mice also displayed a decrease in mRNA for P450scc, a steroidogenic
enzyme responsible for converting cholesterol to pregnenolone in the first steps of steroid
synthesis [2.69].
In the mare, a local role for prolactin in the ovary has been proposed due to the
remarkable and rapid growth of ovarian follicles in response to either exogenous prolactin or
dopamine antagonists during seasonal anestrus. Exactly how exogenous or endogenously
stimulated prolactin facilitates early follicular growth has yet to be determined. King et al. [2.70]
and Oberhaus et al. [2.71] located receptors for prolactin on equine luteal cells and ovarian
granulosa and theca cells, suggesting that prolactin can bind to these cell types and elicit a
response.
2.8 Rationale for Present Experiments
Researchers continue to strive to understand the mechanism by which the mare is able to
transition in and out of cyclicity in order to provide breeders with a convenient and fail-safe
technique for inducing earlier cyclicity. An increase in circulating prolactin has obvious
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stimulatory effects on the mare ovary during seasonal-induced acyclicty. More detailed studies
investigating the relationship between prolactin and ovarian stimulation could provide a clearer
understanding of the mechanism by which prolactin is involved in seasonal transition.
The goals of the experiments presented herein were 1) to assess any perturbations in vernal
transition due to complete suppression of prolactin with cabergoline, 2) to determine any
seasonal variation in ability of cabergoline to suppress prolactin, 3) retrospectively, to determine
factors that might affect whether or not a mare responds to a combined estradiol-sulpiride
treatment, and 4) to assess factors, both molecular and hormonal, that change in response to a
combined estradiol-sulpiride treatment. It was hypothesized that 1) suppression of prolactin
would delay vernal transition, 2) prolactin response to cabergoline would vary across seasons, 3)
factors such as body condition and nutritional status would modulate an ovarian response to
estradiol and sulpiride, and 4) treatment with estradiol and sulpiride, and hence prolactin, would
upregulate LH receptor mRNA in ovarian cells in seasonally anovulatory mares.
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CHAPTER 3: EFFECT OF REPEATED CABERGOLINE TREATMENT ON THE
VERNAL TRANSITION AND HAIR SHEDDING OF MARES (YEAR 1) AND A
SUBSEQUENT COMPARISON OF THE EFFECT OF STARTING DATE ON
PROLACTIN SUPPRESSION (YEAR 2)1
3.1 Summary
Two studies were conducted to determine efficacy of cabergoline for suppressing
prolactin (PRL) and the possible effects on vernal transition in mares. In Experiment 1, six mares
each received either vehicle or cabergoline (5 mg, intramuscularly) every 10 days for 12
treatments beginning February 4, 2013. Blood samples were drawn regularly and mares were
challenged with sulpiride periodically to assess PRL suppression. Weekly hair samples were
obtained to determine shedding. Prolactin was suppressed (P < .05) by cabergoline, but
suppression waned in spring. There was no effect (P > .1) of treatment on day of first ovulation,
LH or FSH. Hair shedding was generally suppressed (P = .05). In 2014 (Experiment 2), 8 of the
same 12 mares were used in a similar experiment to determine if the rise in PRL observed in
Experiment 1 was due to refractoriness to cabergoline or perhaps another factor. Treatment
began on April 6, 2014, corresponding to the increase in PRL in treated mares in Experiment 1.
Mares were treated with cabergoline or vehicle until June 5. Prolactin was suppressed (P < .05)
by cabergoline and the pattern of apparent escape from suppression was similar to year 1. We
conclude that 1) cabergoline at this dose alters hair shedding but does not alter the time of first
ovulation in mares, and 2) relative to our previous reports of cabergoline treatment in the fall,
there is a seasonal effect on the ability of this dose of cabergoline to suppress unstimulated
prolactin secretion.
________________
1

Reprinted with permission from the Journal of Equine Veterinary Science.
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3.2 Introduction
Prolactin appears to be involved in the vernal transition of seasonally anestrous mares,
given that administration of exogenous prolactin [3.1, 3.2] or a dopamine antagonist [3.3-3.5]
can initiate early follicular growth and hasten the date to first ovulation. Besognet et al [3.3]
treated mares with the dopamine antagonist, sulpiride, and were able to increase prolactin
concentrations and advance the first ovulation of the season by approximately 20 days when
compared to untreated mares. Subsequent researchers have tested both sulpiride and
domperidone with varying degrees of success, advancing the first ovulation of the season by as
much as 40 days [3.5]. In addition to the effects on reproduction, elevated prolactin appears to
also have a stimulatory effect on hair coat shedding [3.3, 3.6].
The mechanisms involved with the ovarian response to prolactin in seasonally
anovulatory mares have not been elucidated. Localization of receptors for prolactin on equine
granulosa and theca cells [3.7] as well as the presence of prolactin in follicular and luteal tissue
[3.8, 3.9] are supportive of a model in which prolactin acts directly on the equine ovary during
the vernal transition. Although much research has been devoted to administering dopamine
antagonists, few experiments have described the effects of prolactin suppression on the vernal
transition in mares. Bennett-Wimbush [3.10] treated three groups of anestrous pony mares with
perphenazine twice daily, bromocriptine daily, or vehicle from January 20 until ovulation.
Perphenazine, a dopamine antagonist, advanced the first ovulation by 30 days compared to
controls, while the dopamine agonist, bromocriptine, had no effect on time to first ovulation, but
did appear to delay growth of preovulatory sized follicles. Similarly, Bass [3.11] administered a
long acting dopamine agonist, cabergoline, orally during the natural breeding season, which
suppressed prolactin concentrations but had little to no effect on ovulation or luteal progesterone
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production. While both studies suppressed circulating prolactin concentrations, neither daily
bromocriptine nor oral cabergoline were able to completely suppress prolactin for any length of
time.
Recently, Hebert et al. [3.12] reported complete suppression of prolactin using
cabergoline in a slow releasing vehicle injected intramuscularly. Even when challenged with a
low dose of sulpiride 10 days after cabergoline injection, prolactin remained suppressed.
Additionally, Arana Valencia et al. [3.13] administered a total of seven cabergoline injections 10
days apart and demonstrated no incidences of refractoriness to cabergoline in horses challenged
with sulpiride (one day before the next cabergoline injection) or side effects to the cabergoline
compound. Based on those results, we hypothesized (Experiment 1) that cabergoline in the same
vehicle used in the experiments conducted by Hebert et al. [3.12] and Arana Valencia et al.
[3.13] would suppress prolactin in the long term and thus allow a better assessment of the need
of circulating prolactin in follicular growth and eventual ovulation in mares transitioning from
winter anovulation to a breeding season state in the spring. Given the less-than-total suppression
of prolactin by cabergoline in late spring in Experiment 1, Experiment 2 was performed to test
whether the lack of suppression was due to 1) a refractoriness of the mares to long-term
cabergoline exposure, or perhaps 2) some seasonal change in the mares made them less
susceptible to cabergoline suppression.
3.3 Materials and Methods
Procedures used in these experiments were approved by the Institutional Animal Care
and Use Committee of the Louisiana State University Agricultural Center.
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3.3.1 Animals and treatments
All mares in the two experiments were routinely maintained outdoors on native grass
pasture during the warmer months, and were grazed on winter ryegrass pasture when available in
late winter. In the period between availability of summer grasses and winter ryegrass, hay
prepared from the same native grasses was provided for ad libitum consumption as needed.
Prior to the start of the first experiment, all non-pregnant mares in the resident herd were
assessed by ultrasonic scanning of the ovaries once a week for three weeks starting January 20,
2013, and samples of jugular blood were collected every 4 days. Anovulation was defined as the
absence of any follicle >20 mm, the absence of any corpora lutea, and plasma progesterone
concentrations consistently less than 1 ng/mL.
3.3.2 Experiment 1
Twelve light horse, anovulatory mares were identified and were allotted into two similar
groups based on age (4 to 23 years old), body condition score (4 to 7) and ovarian follicular
growth prior to start of the experiment (February 4, 2013). The groups were then randomly
assigned as treatment (n = 6) and control (n = 6).
On February 4, 2013, and every 10 days thereafter for a total of 12 injections, mares
assigned to the treatment group received 5 mg of cabergoline (Attix Pharmaceuticals, Toronto,
Ontario, Canada) intramuscularly in a slow release vehicle (1 mL). Mares assigned to the control
group received vehicle only (1 mL), intramuscularly, on the same schedule. The vehicle was a
proprietary mixture of hydrophobic, oily liquids designed to provide sustained, slow release of
cabergoline over time (Provided by Richard M. Gilley, BioRelease Technologies LLC,
Birmingham, AL).
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3.3.3 Experiment 2
Eight of the same 12 mares from Experiment 1 were available and were used the
following year. Mares remained in the same treatment groups in both experiments. On April 6,
2014, and every 10 days thereafter, mares in the treatment group (n = 4) received cabergoline as
described in Experiment 1. Mares assigned to the control group (n = 4) received vehicle only. A
total of seven treatment injections were given, with the last injection on June 5, 2014.
3.3.4 Ultrasonography and Estrous Behavior
In Experiment 1, ovarian activity was monitored via ultrasonography (Aloka 550V with
5-Mhz linear-array transducer; Hitachi-Aloka, Wallingford, CT) once a week until a follicle >25
mm emerged. Once a follicle exceeded 25 mm, the mare was scanned daily until the follicle
ovulated or regressed to <25 mm.
Also upon detection of a follicle >25 mm, the mare was checked for displays of estrus
with one of two stallions daily until 2 days after her second ovulation. A single evaluator graded
receptivity of the mare using a -3 to 3 scale, whereby, -3 = extreme aggression toward stallion, -2
= ear pinning, -1 = avoidance of stallion, 0 = indifferent to stallion, 1 = raising tail, 2 = raising
tail as well as clitoral eversion, 3 = posturing and urinating.
In Experiment 2, only the prolactin response to cabergoline was characterized. Given the
lack of effect on reproduction in Experiment 1, ultrasonography, estrus detection and circulating
gonadotropins were not assessed in Experiment 2.
3.3.5 Blood Sampling
3.3.5.1 Experiment 1. Jugular blood samples were collected in 10-mL evacuated tubes
containing sodium heparin (Vacutainer, Becton and Dickinson, Franklin Lakes, NJ) beginning on
Feb 5, 2013 (day 1), and every 4 days after until May 28 (day 113) to determine circulating
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prolactin concentrations. Additionally, on the day of first ovulation and for 16 successive days
after, a single blood sample was drawn to determine circulating concentrations of FSH, LH, and
progesterone. Plasma was harvested by centrifugation at 1200 x g for 15 minutes and was stored
at -20°C.
On days 29, 59, 79, 89 and 119 of the experiment, which was always nine days after an
injection of cabergoline, mares were administered a low dose of sulpiride (2 μg/kg of body
weight of a racemic mixture; Sigma Chemical Co., St. Louis, MO) intravenously in saline.
Jugular blood was collected at 0, 5, 10 and 20 min relative to treatment to determine the prolactin
response to sulpiride. Blood collection and storage was done in the same manner described
above.
3.3.5.2 Experiment 2. Jugular blood samples were collected as described in Experiment
1 beginning on Apr 7, 2014 (day 1), and every other day after until June 14 (day 69), to
determine circulating prolactin concentrations. Similar to Experiment 1, mares were challenged
with a low dose of intravenous sulpiride on days 29 (May 5) and 69 (June 14) and blood
collected at 0, 5, 10 and 20 min relative to treatment. Plasma was harvested and stored as
described for Experiment 1.
3.3.6 Hair Collection
In Experiment 1, once weekly for eight weeks beginning February 6, a tuft of hair was
pulled three times from the left shoulder of each horse, stored, and later weighed to determine
any differences in shedding of the winter coat. Hair was easily pulled from horses that were
beginning to shed their winter coat and remained intact in horses with retained winter coats. On
day 92 (May 7), a 3 x 3-cm patch of hair from approximately 6 inches below where the back
meets the loin (rib area) was shaved with clippers and weighed. Due to a later start date in
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Experiment 2, mares were already beginning to shed their winter coat, thus hair shedding was
not assessed.
3.3.7 Sample and Data Analyses
Due to the different objectives of the two experiments, data collection in Experiment 1
was more extensive than for Experiment 2. Specifically, Experiment 2 only monitored plasma
prolactin concentrations in routine blood samples and after sulpiride challenge. All data
collection and analyses are described herein.
Frozen plasma samples were thawed and analyzed for prolactin, FSH, LH, and
progesterone as appropriate. Prolactin, FSH, and LH were measured by radioimmunoassay in
assays previously validated by our laboratory [3.14-3.16]. Intra- and interassay coefficients of
variation and levels of detection were 7%, 12% and 0.2 ng/mL for prolactin; 6%, 9%, and 0.2
ng/mL for LH; and 7%, 11%, and 1.4 ng/mL for FSH. Progesterone was analyzed using
commercially available kit reagents (ImmuChem Double Antibody, 125I RIA Kit, MP
Biomedicals, Inc, Costa Mesa, CA).
Data for dependent variables collected over many different time points (plasma
concentrations of prolactin, LH, FSH, and progesterone, and hair weight) were analyzed by oneway analysis of variance (ANOVA) with repeated sampling using the general linear model of
SAS (SAS Instit., Cary, NC). Data for prolactin concentrations obtained during sulpiride
challenges were analyzed as a double-split-plot design, with treatment as the main effect,
repetitive challenges as the first repetition, and multiple sampling times within each challenge as
the second repetition. Day of first ovulation was analyzed using a one-way ANOVA. When
appropriate, differences between treatment groups within time periods were tested for
significance by the least significant difference test [3.17].
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Experiment 1 versus 2 similarities and differences in prolactin concentrations were
analyzed by one-way ANOVA (year as the main effect) with repetitive sampling. Separate
analyses were run for just control mares and just treated mares in both years. Differences
between years within time periods were assessed by the least significant difference test [3.17].
3.3 Results
3.3.1 Experiment 1
Towards the end of the first experiment, one mare in the control group developed severe
lameness unrelated to the experiment and was subsequently euthanized. Her data for LH, FSH,
progesterone, day of ovulation, and the first three sulpiride challenges were complete. There was
no data for her in the final (fourth) sulpiride challenge, as well as the last 9 days of daily
samples; she was included in the analyses otherwise.
There was a significant interaction between treatment and day (P < .0001) for mean
plasma prolactin concentrations in samples obtained every 4 days (Figure 3.1). Prolactin
concentrations were generally low in both groups and not different (P > .1) through day 61 (April
6, 2013). Thereafter, as prolactin concentrations gradually increased in control mares through
day 113, those in cabergoline-treated mares decreased and then gradually rose again with each
cabergoline injection, such that they were suppressed (P < .05) relative to controls for the first
one or two blood samples after injection, but not the entire 10-day period.
Mean day of first ovulation did not differ (P > .1) between control mares (April 7 ± 7
days) and treatment mares (April 18 ± 7 days). Mean plasma LH, FSH, and progesterone
concentrations in samples obtained daily from the day of first ovulation until day 16 are
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Fig. 3.1. Mean plasma concentrations of prolactin in Experiment 1 in samples obtained every 4
days from mares treated with 5 mg of the dopamine agonist, cabergoline (n = 6), or vehicle
(controls; n = 6) every 10 days (treatment days indicated by arrow) from February 4, 2013 (day
0), through May 28, 2013 (day 113). After April 6 (day 61), prolactin in mares treated with
cabergoline continued to decline with treatment; however, the effects did not last 10 days. A
significant treatment by day interaction (P < .0001) was detected and differences are indicated
with asterisks. Pooled standard error of the mean from the analysis of variance was 1.0 ng/mL.

presented in Figure 3.2. Luteinizing hormone and FSH concentrations did not differ (P > .1)
between cabergoline and vehicle treated mares, nor were any differences found in circulating
progesterone concentrations. Mean interovulatory intervals were not different between treated
(24 ± 0.67 days) and control (24.5 ± 1.9 days) mares; no perturbations in estrous behavior were
observed.
A robust prolactin response to sulpiride was observed in mares receiving vehicle only
(Figure 3.3) and was greatly suppressed (P < .01) in cabergoline-treated mares. With each
subsequent sulpiride challenge, the prolactin response gradually increased in cabergoline-treated
mares, although it remained greatly suppressed (P < .01) when compared to control mares.
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Fig. 3.2. Mean plasma concentrations of LH, FSH, and progesterone in samples collected in
Experiment 1 on the day of first ovulation (day 0 for each mare) and for 16 successive days
thereafter in mares treated with 5 mg of cabergoline (n = 6) and mares treated with vehicle
(controls; n = 6). No differences (P > .1) were detected between groups for any hormone. Pooled
standard errors of the mean from the analyses of variance were 0.73, 6.8, and 1.1ng/mL for LH,
FSH, and progesterone concentrations, respectively.

Weight of hair samples obtained weekly generally weighed less (P = .05, Figure 3.4) in
cabergoline-treated mares than in control mares; however, weight of hair sample shaved from the
rib area on May 7 did not differ between treated and control mares.
3.3.2 Experiment 2
Mean prolactin concentrations in samples obtained every other day from April 6 until
June 13 are presented in Figure 3.5. Prolactin was suppressed (P < .05) in mares treated with
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Fig. 3.3. Mean prolactin response to sulpiride in cabergoline- and vehicle-treated (control) mares
on days 29, 59, 79, 89 and 119 in Experiment 1. Numbers within numbered days on the
horizontal axis represent minutes relative to sulpiride treatment. Prolactin response to sulpiride
was greatly suppressed (P < .01) in cabergoline-treated mares. At each challenge, differences (P
< .01) between groups occurred at all time points except for the pre-treatment (0 min) sample.
Pooled standard error of the mean from the analysis of variance was 3.3 ng/mL.

Fig. 3.4. Weight of hair samples obtained weekly in Experiment 1 for 8 weeks beginning
February 6, 2013. Hair samples generally weighed less (P = .05) in cabergoline-treated mares
than in controls. Differences are indicated by the asterisks. Pooled standard error of the mean
from the analysis of variance was 5.7 mg.
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Fig. 3.5. Mean plasma concentrations of prolactin in Experiment 2 in samples obtained every
other day from mares treated with 5 mg of cabergoline (n = 4) or vehicle (controls; n = 4) every
10 days (treatment days indicated by arrow) from April 6, 2014 (day 0) through June 5, 2014
(day 69). Prolactin concentrations were mostly suppressed (P < .05) in cabergoline treated mares
except in samples near the next cabergoline injections. Differences between groups within days
are indicated by the asterisks. Pooled standard error of the mean from the analysis of variance
was 4.5 ng/mL.

cabergoline, with the pattern of suppression being very similar to Experiment 1. Prolactin
response to sulpiride on day 29 (May 4) and day 69 (June 14) was greatly suppressed (P < .01) in
mares treated with cabergoline, while vehicle-treated mares had a robust response to sulpiride.
When super-imposing the sulpiride challenges in 2014 over the same sulpiride challenge days in
2013 (Figure 3.6), the prolactin response to sulpiride is very similar, particularly in cabergolinetreated mares.
Analysis of the two separate years in a single ANOVA revealed that prolactin in vehicletreated mares varied (P < .05, Figure 3.7) from Experiment 1 (2013) to Experiment 2 (2014),
with unstimulated prolactin being generally higher in 2014. The pattern of prolactin suppression
in cabergoline-treated mares, however, was very similar (P > .1, Figure 3.8) from year to year.
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Fig. 3.6. Comparison of prolactin response to sulpiride in May and June, 2013 and 2014, in
cabergoline and vehicle-treated mares. Numbers on the horizontal axis represent minutes relative
to sulpiride treatment. Prolactin responses to sulpiride were suppressed (P < .01) in mares treated
with cabergoline. Differences between cabergoline and vehicle-treated mares occurred at all time
points except pre-treatment (0 min) samples. The suppressive effect of cabergoline on prolactin
concentrations after sulpiride was similar for the two years. Pooled standard error of the mean
from the analysis of variance was 10.3 ng/mL.

Fig. 3.7. Comparison of the unstimulated plasma prolactin concentrations in control mares only
over the two years of experimentation (2013 versus 2014). Samples were aligned relative to
April 6 for both years. Plasma prolactin in control mares varied (P < .05) from year to year,
with those in Experiment 2 being generally higher than in Experiment 1. Differences are noted
by the asterisks. In Experiment 2, plasma samples were collected more frequently and for a
longer period of time than in Experiment 1, which accounts for the greater number of data points
in 2014. While all data are presented in the graph, only data points from 2014 that had a
matching data point on the same day from 2013 were included in the analysis of variance. Pooled
standard error of the mean from the analysis of variance was 2.3 ng/mL.
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Fig. 3.8. Comparison of the unstimulated plasma prolactin concentrations in cabergoline-treated
mares only over the two years of experimentation (2013 vs 2014). Samples were aligned relative
to April 6 for both years. Plasma prolactin in mares treated with cabergoline were similar
between year 1 and 2. In Experiment 2, plasma samples were collected more frequently and for a
longer period of time than in Experiment 1, which accounts for the greater number of data points
in 2014. While all data points are presented in the graph, only data points from 2014 that had a
matching data point on the same day from 2013 were included in the analysis of variance. Pooled
standard error of the mean from the analysis of variance was 1.7 ng/mL.

3.4 Discussion
Given the ability of exogenous prolactin [3.1, 3.2], as well as endogenous prolactin
stimulated by dopaminergic antagonists [3.3-3.6], to hasten ovulation in seasonally anovulatory
mares, the question arises as to what role prolactin actually plays in the normal vernal transition
period in mares. If prolactin was an obligatory factor for ovulation, then removing it from the
circulation would be expected to either prevent or at least delay the date of first ovulation. Our
hypothesis, based on results of experiments done in the fall of the year [3.12, 3.13], was that 5
mg of cabergoline in the slow-release vehicle used in those experiments would totally suppress
prolactin secretion during treatment. Prolactin concentrations were generally suppressed in
Experiment 1 up to April 6, the time of normally expected first ovulation at the LSU AgCenter
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Horse Farm (personal observation). Thus, although our original hypothesis concerning
cabergoline’s suppression of prolactin was not supported (for later time periods after April), the
suppression of prolactin prior to April 6 had no effect on date of first ovulation. Prolactin
concentrations in vehicle-treated mares began to rise around March 17 (day 41) with a large peak
of prolactin occurring on April 6 (day 61). Mean first day of ovulation for vehicle-treated mares
was April 7. Similarly, prolactin in cabergoline-treated mares increased on April 14 (day 69) and
mean first day of ovulation for treated mares was April 18. Given that mean first day of
ovulation for both groups of mares occurred just after a rise in prolactin, it could be that mares
recovered from cabergoline suppression quickly enough such that sufficient prolactin was
available for normal follicular development and ovulation. Alternatively, it could be that
circulating prolactin is not an obligatory factor for follicular growth and ovulation in these mares
at this time. Most of the data collection for LH and FSH during the post-ovulatory cycle was in
April, when prolactin concentrations were no longer totally suppressed, thus the lack of
treatment effect could be due to adequate prolactin being available, or to a lack of involvement
of prolactin in the secretion of these gonadotropins. The same can be said of progesterone
concentrations in the first diestrous period.
A problem encountered in human medicine of using dopaminergic agonists for appetite
suppression was gradual resistance to the agonist, or tolerance to its effects [3.18, 3.19], which
required subsequently higher dosages to achieve the same suppression. If refractoriness to
cabergoline was the cause of the eventual rise in prolactin in April and thereafter in Experiment
1, we would have expected a period of total suppression in treated mares for approximately 60
days after start of treatment (well into June) during the second year (Experiment 2) followed by a
rise in prolactin as observed the previous year. Although there was considerable variation in
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prolactin concentrations from year 1 to year 2, that variation can be attributed to the control
mares (Figure 3.7). The patterns of suppression in cabergoline-treated mares in years 1 and 2
were almost identical (Figure 3.8), indicating that a refractoriness to cabergoline treatment was
not likely the cause of an eventual rise in prolactin. Therefore, other physiological changes, such
as seasonal change(s) in other factor(s), need to be considered.
Clavier et al. [3.20] reported a seasonal variation in dopaminergic input to the
adenohypophysis in mares based on the mean sulpiride dose required to counteract the
endogenous dopamine input and to achieve a 50% maximal prolactin response during spring,
summer, fall and winter. Mean 50% maximal dose was lowest in June, which would equate to a
lower endogenous dopaminergic input during that season relative to the others. Mean 50%
maximal doses were highest in September and December. Although any reduced input of
endogenous dopamine to the lactotropes in the spring should have been overwhelmed by the
exogenous cabergoline in Experiment 1, the original dose of 5 mg every 10 days, which was
totally suppressive of prolactin in the fall [3.12, 3.13], may have become inadequate after April
6. In addition to seasonal variations in dopamine input to the adenohypophysis, seasonal changes
in lactotrope sensitivity to dopamine (perhaps reduced receptors) is a possibility [3.21].
Interestingly, the prolactin response to sulpiride after April 6 was still greatly suppressed in
cabergoline-treated mares even when unstimulated (every four-day samples) prolactin had begun
to rise. This may indicate a long-term, and continuing, suppression of releasable stores of
prolactin separate from the stores available for daily (basal) release. Alternatively, if indeed
dopamine receptors are reduced at this time due to some seasonal factor, then the response to
blockage of those receptors (by sulpiride) may be reduced (less sensitive) as well. Assessment of
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total prolactin content in the adenohypophysis and measurement of dopamine receptor numbers
during this period are needed to help explain our current observations.
Hair coat shedding was perturbed by cabergoline treatment in Experiment 1. This is
consistent with other observations [3.3, 3.6] in which pronounced shedding of winter coat was
observed in mares treated with sulpiride (resulting in increased prolactin secretion) or with
recombinant porcine prolactin [3.2]. Weight of hair pulled once weekly tended to weigh less in
cabergoline-treated mares, suggesting retention of winter coat. Unfortunately, no pre-treatment
hair samples were collected for weight determination; however, visual inspection clearly
revealed a retained winter coat in treated mares well into late spring and even early summer.
Similarly, Thompson et al [3.2] reported retention of patches of winter hair coat as late as May in
pony mares that had developed high antibody titers against exogenous recombinant porcine
prolactin. The fact that winter hair shedding was slowed in mares in Experiment 1 after April is
an indication that prolactin suppression was indeed causing a biological response. Apparently,
hair shedding is more sensitive to perturbations in plasma prolactin concentrations than is
follicular growth, ovulation, and the associated hormonal secretion rates.
In conclusion, cabergoline as administered in the present experiments was effective in
suppressing prolactin secretion, however, complete or near complete suppression was only
achieved in very early spring; thereafter, inhibition of prolactin still occurred, but the duration of
suppression waned at the dose of cabergoline and the vehicle used. Refractoriness does not
appear to be the cause of the prolactin escape from cabergoline. It is likely that an unknown
physiological factor, such as seasonal variation in dopaminergic input [3.20], or perhaps
sensitivity to dopamine [3.21], is over-riding the inhibitory dopaminergic effect of cabergoline,
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given that the pattern of prolactin escape was almost identical from year 1 to year 2. No negative
effect on reproduction was observed, which is consistent with other reports [3.10, 3.11].
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CHAPTER 4: SEASONAL ASSESSMENT OF CABERGOLINE SUPPRESSION OF
PROLACTIN IN MARES: UNSTIMULATED VERSUS SULPIRIDE STIMULATED
AND THYROTROPIN RELEASING HORMONE STIMULATED RESPONSES
4.1 Summary
Six experiments were performed to assess a possible seasonal variation in prolactin
suppression from administration of cabergoline. Experiments 1-4 were carried out near the
vernal equinox, summer solstice, autumnal equinox and winter solstice, respectively. For each
of those experiments, 10 light horse mares (n = 6 cabergoline; n = 4 vehicle) were administered
1.5 mg/500 kg BW cabergoline in oil or oil only, i.m. Blood samples were drawn at -10 minutes,
0, 1, 3, 6,12 hours, and every 12 hours thereafter until 168 hours (7 days). Cabergoline
suppressed (P < .001) prolactin in Experiments 1 and 2 with prolactin returning to concentrations
similar to controls around 120 hours (5 days). In Experiment 3 (October), prolactin was
suppressed (P < .001) in cabergoline-treated horses compared to vehicle-treated mares at 3, 6, 36,
108, 156 and 168 hours post treatment. Experiment 4 (December) revealed differences (P <
.001) between cabergoline- and vehicle-treated mares only at 6 and 120 hours post treatment ,
given that prolactin concentrations are naturally low in winter. In Experiment 5 (July), 13 mares
were treated (n = 5 vehicle; n = 4 compounded cabergoline; n = 4 cabergoline in oil) and blood
was drawn as described for Experiments 1-5 but continued until 264 hours; sulpiride challenges
(.01 mg/kg BW, i.v.) were administered every-other-day. Cabergoline suppressed (P < .0001)
prolactin in both cabergoline formulation groups and the patterns of suppression were virtually
identical. Unstimulated prolactin returned to concentrations similar to controls around 132 hours;
however, the prolactin response to low dose sulpiride continued to remain greatly suppressed (P
< .0001) even after unstimulated levels had returned to normal. In Experiment 6 (October), 6
mares each received either 5 mg cabergoline in oil or oil only, and blood was drawn regularly
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until 264 hours; TRH challenges (2 mg/500 kg BW, i.v.) were administered every-other-day.
Cabergoline suppressed (P < .05) prolactin in treated mares for at least 96 hours compared to
controls; however, at that time, circulating levels of prolactin in controls dropped remarkably and
were indistinguishable from cabergoline-treated mares. The prolactin response to TRH was
completely suppressed (P < .05) in treated mares through 120 hours, but began to recover in
subsequent challenges. The recovery of TRH-stimulated prolactin was observed earlier than
sulpiride-stimulated prolactin in Experiment 6. In conclusion, no seasonal variation was
observed for the duration of suppression or the degree of suppression of prolactin by a fixed dose
of cabergoline. However, both sulpiride and TRH-stimulated prolactin continued to be
suppressed in cabergoline-treated mares long after unstimulated prolactin concentrations had
returned to normal. This apparent dichotomy is consistent with a model of at least two
subpopulations of lactotropes regulated differentially by dopaminergic input, as has been
reported in other species.
4.2 Introduction
Cabergoline is a potent dopamine receptor agonist that acts upon dopaminergic type 2
(D2) receptors [4.1]. In humans, cabergoline is used frequently in low doses to treat
hyperprolactinemia [4.2, 4.3] and does not appear to be associated with deleterious side effects,
such as heart valve dysfunction reported for other dopamine receptor agonists such as pergolide
and bromocriptine [4.4-4.7].
Hebert et al. [4.8] and Arana Valencia et al. [4.9] assessed the effects of cabergoline on
plasma prolactin in mares and geldings as a potential replacement therapy for pergolide in the
treatment of pituitary pars intermedia dysfunction (PPID) in horses. Both authors began
cabergoline treatments during the fall and reported complete suppression of prolactin in the face
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of low dose challenges with the dopamine antagonist sulpiride. A single injection of 5 mg of
cabergoline suppressed sulpiride-induced prolactin for 10 days [4.8]. In comparison, 2 mg of
pergolide, the currently available drug for PPID treatment, reduced prolactin for 24 hours when
injected and only 12 hours when given orally [4.8]. Subsequently, Arana Valencia et al. [4.9]
administered a total of 7 cabergoline injections 10 days apart beginning in October and
demonstrated no incidences of refractoriness to cabergoline in horses challenged with sulpiride
(one day before the next cabergoline injection) or side effects to the cabergoline compound.
Given the remarkable magnitude and duration of prolactin suppression by cabergoline,
Oberhaus et al. [4.10] administered 10 treatments 10 days apart to seasonally anovulatory mares
starting in February to assess possible perturbations in vernal transition. Blood sampling every 4
days initially revealed low concentrations of prolactin in both treated and control groups, as
would be expected in mares during late winter. In early spring, as plasma prolactin
concentrations rose to detectable levels, cabergoline suppressed prolactin in treated mares;
however, the suppression gradually waned before the next treatment. In a repeat experiment the
following year, Oberhaus et al. [4.10] determined that the lack of 10-day suppression was not
due to refractoriness to cabergoline, and suggested that other cues, such as season, may influence
the prolactin response to dopaminergic agonists. In the same two experiments, even after the
suppression of unstimulated prolactin had waned, the prolactin response to low dose sulpiride
injection was still 85% suppressed when compared to control mares [4.10].
Given these conflicting patterns of prolactin suppression, the series of trials described
herein was designed 1) to assess any potential seasonal variation in the prolactin response to
cabergoline, 2) to compare suppressive effects of cabergoline in oil to cabergoline in a known,
slow-releasing vehicle and 3) to evaluate differences in prolactin stimulation in cabergoline-
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treated horses to sulpiride and TRH, two known prolactin secretagogues that act via distinct,
separate receptor systems.
4.3 Materials and Methods
Procedures used in these experiments were approved by the Institutional Animal Care and
Use Committee of the Louisiana State University Agricultural Center.
4.3.1 Animals
All mares used in these experiments were maintained outdoors on native grass pasture
during the warmer months, and were grazed on winter ryegrass pasture when available in late
winter. In the period between availability of summer grasses and winter ryegrass, hay prepared
from the same native grasses was provided for ad libitum consumption as needed.
4.3.2 Experiments 1-4
Ten light horse mares ranging in age from 6 to 25 years old and weighing 380 to 550 kg
were treated with an intramuscular injection of either cabergoline (n = 6; 1.5 mg/500 kg BW) or
vehicle only (controls; n = 4). Cabergoline (Sigma-Aldrich, St. Louis, MO) was dissolved in a
minimal amount of diethyl ether and then mixed into vegetable oil (Crisco; J.M. Smucker
Company, Orrville, OH). Vehicle-treated mares received oil only with ether added.
Experiments 1-4 began on March 22, July 15, October 8 and December 27, 2015,
respectively. Ten minutes prior to treatment, a single blood sample was collected from each
mare via jugular venipuncture into 6-mL evacuated tubes containing sodium heparin as an
anticoagulant (Vacuette, Greiner Bio-One, Monroe, NC). Blood sampling was continued at 0, 1,
3, 6, 12 hours and then every 12 hours after cabergoline and vehicle injections until 168 hours (7
days). For all blood samples collected throughout the experiment, plasma was harvested by
centrifugation at 1200 x g for 15 minutes and was subsequently stored at -20°C.
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4.3.3 Experiment 5
On July 16, 2016, 13 light horse mares of similar ages and weights as described above
received a pretreatment intravenous injection of sulpiride in saline (0.01 mg/kg BW; SigmaAldrich, St. Louis, MO) and blood was drawn at 0, 10 and 20 minutes post treatment. The
following day, mares were assigned to treatment groups and received either 5 mg of cabergoline
in oil as described above (n = 4), 5 mg of cabergoline (Attix Pharmaceuticals, Toronto, Ontario,
Canada) in a proprietary slow release vehicle (n = 4), or oil only (n = 5). All injections were 1
mL. The slow release vehicle was a proprietary mixture of hydrophobic, oily liquids designed to
provide sustained, slow release of cabergoline over time (Provided by Richard M. Gilley,
BioRelease Technologies LLC, Birmingham, AL). Blood samples were drawn at -10 minutes, 0,
1, 3, 6, and 12 hours and then every 12 hours after until 264 hours (11 days). One day after
treatment as well as every other day until day 11, all mares were challenged with intravenous
low dose sulpiride as described above. Plasma was harvested by centrifugation at 1200 x g for
15 minutes and was stored at -20°C.
4.3.4 Experiment 6
On October 16, 2016, 12 light horse mares of similar ages and weights as described
above received a pretreatment intravenous injection of thyrotropin releasing hormone (TRH, 2
mg/500 kg BW; Sigma-Aldrich, St. Louis, MO) in saline. Blood was collected 0, 10, 20 and 30
minutes relative to injection. The following day, mares assigned to treatment group (n = 6)
received 5 mg cabergoline in oil, intramuscularly, while control mares (n = 6) received oil only.
Preparation of cabergoline in oil was the same as described in the first 5 experiments. Blood was
sampled at 0, 1, 6, and 24 hours and then every 24 hours thereafter until 264 hours (day 11). One
day after treatment as well as every other day until day 11, all mares were challenged with
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intravenous TRH as described above. Plasma was harvested by centrifugation at 1200 x g for 15
minutes and was stored at -20°C.
4.3.5 Sample and Data Analysis
Frozen plasma samples were thawed and analyzed for prolactin by radioimmunoassay
previously validated for equine samples by Colborn et al. [4.11]. Intra- and interassay
coefficients of variation and minimal levels of detection for prolactin were 7%, 12% and 0.2
ng/mL.
Data for plasma concentrations of prolactin, collected over sequential time points, were
analyzed by one-way analysis of variance (ANOVA) with repeated sampling using the general
linear model of SAS (SAS Instit., Cary, NC). Data for prolactin concentrations obtained during
sulpiride and TRH challenges were analyzed in double-split-plot design ANOVA, with treatment
as the main effect, repetitive challenges as the first repetition, and multiple sampling times within
each challenge as the second repetition. When appropriate, differences between treatment groups
within time periods were tested for significance by the least significant difference test [4.12].
4.4 Results
Mean plasma concentrations of prolactin for Experiments 1-4 are presented in Figure 4.1.
Cabergoline effectively suppressed (P < .001) prolactin in treated horses in Experiment 1 and 2
with prolactin returning to concentrations similar to controls around 120 hours. In Experiment 3
(October), prolactin was suppressed (P < .001) in cabergoline-treated horses compared to
vehicle-treated mares at 3, 6, 36, 108, 156 and 168 hours post treatment. Experiment 4
(December) revealed differences (P < .001) between cabergoline- and vehicle-treated mares only
at 6 and 120 hours post treatment.
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Figure 4.1 Mean plasma prolactin concentrations in mares administered 1.5 mg of cabergoline in
diethyl ether-vegetable oil vehicle (Cabergoline) or vehicle only (Control) aound the time of the
spring equinox (panel A), summer solstice (panel B), autumnal equinox (panel C), and winter
solstice (panel D). Asterisks indicate differences (P < .05) between groups for specified periods.
Pooled standard errors of the mean were 0.69 ng/mL, 1.6 ng/mL, 0.33 ng/mL, and 0.32 ng/mL
for panels A-D, respectively.
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In Experiment 5 (July), cabergoline suppressed (P < .0001, Figure 4.2) prolactin in both
compounded cabergoline and cabergoline in oil groups with pattern of suppression being
virtually identical. Unstimulated prolactin returned to concentrations similar to controls around
132 hours; however, the prolactin response to low dose sulpiride continued to remain greatly
suppressed (P < .0001, Figure 4.3) well after unstimulated levels had returned to normal.
In Experiment 6 (October), cabergoline suppressed (P < .01, Figure 4.4) prolactin in
treated mares for at least 96 hours compared to controls; however, at that time, circulating levels
of prolactin in controls dropped remarkably and were indistinguishable from cabergoline-treated
mares. The prolactin response to TRH was completely suppressed (P < .05) in treated mares
through 120 hours (Figure 4.5), but began to recover in subsequent challenges.

Figure 4.2 Mean plasma prolactin concentrations of mares administered 5 mg compounded
cabergoline in a proprietary vehicle (Compounded cabergoline), 5 mg of cabergoline in diethyl
ether-vegetable oil vehicle (Cabergoline in oil), or oil only (Control) in July (Experiment 6).
Asterisks indicate differences (P < .01) between vehicle-treated mares and both groups of
cabergoline-treated mares for specified periods. Pooled SEM 5.5 ng/mL.
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Figure 4.3 Mean plasma prolactin concentrations in response to low dose (.01 mg/kg BW)
sulpiride injection (i.v.) administered 24 hours before and then on multiple days after injection of
5 mg cabergoline in proprietary vehicle (Compounded cabergoline), 5 mg cabergoline in diethyl
ether-vegetable oil vehicle (Cabergoline in oil), or oil only (Control) in Experiment 6. Data are
for the 10-minute samples collected after sulpiride injection (peak values). Means with different
letters indicate differences (P < .0001) within each specified time period. Pooled SEM was 15
ng/mL.

Figure 4.4 Mean plasma prolactin concentrations in mares administered 5 mg of cabergoline in
diethyl ether-vegetable oil vehicle (Cabergoline) or vehicle only (Control) in October. Asterisks
indicate differences (P < .01) between groups for specified periods. Pooled SEM was 0.33 g/mL.
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Figure 4.5 Mean plasma prolactin concentrations after treatment with 2 mg/500 kg BW TRH in
mares 24 hours before and on multiple time periods after treatment with 5 mg cabergoline in
diethyl ether-vegetable oil vehicle (Cabergoline in oil), or oil only (Control). Data are for the 30minute sample (peak) only. Means with different letters indicate differences (P < .05) between
groups within each specified time period. Pooled SEM was 15.7 ng/mL.

4.5 Discussion
In the experiments of Hebert et al. [4.8] and Arana Valencia et al. [4.9], both performed
in the fall months, 5 mg of cabergoline in the proprietary mixture of oily liquids administered
intramuscularly to horses totally suppressed the sulpiride-induced prolactin response for at least
10 days. Although unstimulated (basal, time 0) samples were measured, little change was
detected due to the seasonally low prolactin concentrations at that time. Application of the
cabergoline suppressive model to test the role of prolactin in vernal transition in spring [4.10]
indicated that unstimulated prolactin secretion was totally suppressed after injection of 5 mg of
cabergoline for several days, but unlike in the fall experiments, unstimulated prolactin
concentrations returned to control levels in 9 days or less. Thus, the experiments presented
herein were designed to determine if magnitude and duration of prolactin suppression by
administration of cabergoline varied from season to season.
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In the first 4 experiments, in lieu of the 5 mg cabergoline treatments administered by
Hebert et al. [4.8] and Arana Valencia et al. [4.9], 1.5 mg/500 kg BW of cabergoline was chosen
due to limited availability of cabergoline in proprietary vehicle as well as to assess a smaller dose
of cabergoline. In both spring and summer, 1.5 mg/500 kg BW cabergoline suppressed prolactin
concentrations for a minimum of 96 hours (4 days). In March and July, prolactin returned to
values similar to controls by 108 hours and 120 hours, respectively. Thus, suppression of
prolactin was similar in duration between spring and summer. Prolactin secretion naturally
begins to decline during the fall and reaches its nadir during the winter [4.13-4.15]. Thus,
differences in prolactin concentrations between cabergoline- and vehicle-treated mares in fall
and winter were not as obvious compared to spring and summer. However, suppression of
prolactin was detected in cabergoline-treated mares in the fall and, to a lesser degree, in the
winter, similar to what was described by Arana Valencia et al. in fall [4.9]. Some vehicle-treated
mares continued to have variable and somewhat elevated prolactin concentrations which made
comparisons with cabergoline-treated mares possible during those specific time periods.
In all experiments, a surge of prolactin was observed in vehicle-treated mares in the
samples collected 3-6 hours after treatment but not thereafter. This was very consistent from
experiment to experiment, indicating it was not due to a single, spurious event. To test whether
the oil vehicle, or perhaps the diethyl ether added to the vehicle, was the cause of this
unsuspected rise in prolactin, a brief side-trial (unpublished) was conducted testing the individual
components versus a no-injection group. It was concluded that neither component was
responsible for the prolactin rise. An alternate explanation is that during the 3-6 hour window
post treatment on that first day, the horses were removed from the holding chute (in which they
had been confined from the start of treatment) and were allowed to graze in the nearby pasture
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until the next blood sampling period. Prolactin has been shown to increase consistently after
feeding [4.16-4.18], whether it be a full meal of pelleted concentrate or minimal consumption of
other feedstuffs [4.17]. Direct gastric infusion of feedstuffs into the stomach by nasogastric
intubation did not induce a prolactin response [4.16].
In Experiment 5 (July 2016), 5 mg of cabergoline was chosen to compare the formulation
in oil to the dose of compounded cabergoline used by Hebert et al. [4.8] and Arana Valencia et
al. [4.9]. Both formulations suppressed prolactin concentrations for 120 hours (5 days) with the
pattern of suppression being virtually identical. Again, there was no indication of a seasonal
variation. In Experiment 6 (October 2016), 5 mg of cabergoline in oil suppressed circulating
prolactin for at least 96 hours (4 days) at which point concentrations of prolactin in vehicletreated mares decreased rapidly and were indistinguishable from cabergoline-treated mares. This
consistent drop in prolactin concentrations in control horses had not been observed in any other
experiments, thus further analysis was warranted. Retrospective evaluation of weather conditions
during that time revealed that a strong cold front passage, including a thunderstorm followed by
a drop in ambient temperature and a shift to northerly winds all occurred coincident with the
drop [4.19]. Although no solid evidence has been reported for a temperature effect on prolactin
secretion in horses, it is well documented that cold temperatures suppress prolactin secretion in
dairy cattle [4.20].
In Experiments 5 and 6, mares were challenged every other day with the dopamine
antagonists, sulpiride and TRH, respectively. In both experiments, the prolactin response to
either secretagogue was totally absent in cabergoline-treated mares up to 120 hours after
treatment. After that, the prolactin response to sulpiride and TRH began to slowly recover, but
remained greatly suppressed when compared to vehicle-treated mares. Four to five days into the
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experiments, unstimulated prolactin had returned to concentrations similar to vehicle-treated
mares, but the prolactin response to either sulpiride or TRH remained suppressed in cabergolinetreated mares up through 11 days. This same pattern of continued suppression of sulpirideinduced prolactin was described by Oberhaus et al. [4.10]: cabergoline-treated mares continued
to display greatly suppressed prolactin-responses to sulpiride well in to the early summer months
and well after the suppressive effects of cabergoline had waned. This presents an interesting
dichotomy of prolactin secretion. It is possible that cabergoline administration results in a downregulation or desensitization of dopamine receptors on lactotropes, thus preventing those
lactotropes from responding to either dopamine agonists or antagonists. But given the same
pattern of suppression observed with TRH, a secretagogue that does not interact with dopamine
receptors on lactotropes, this does not seem to be the most likely explanation.
Another possible consideration for the dichotomy is the existence of subpopulations of
lactotropes which could potentially respond differently to secretagogues and inhibitors and/or
could recover faster from inhibition. Subsets of lactotropes have been described for several
species [4.21-4.24], including the horse [4.25]. These subsets differ morphologically based on
the size of the cell as well as the size and shape of the secretory granules. Christian et al. [4.24]
described three morphological subtypes (Type I, II and III) of prolactin-secreting cells in the rat
pituitary. By examining exocytosis of prolactin granules, it appeared all three types were
inhibited by dopamine, but only Type II and Type III lactotropes were stimulated with TRH or
vasoactive intestinal peptide (VIP), another known prolactin secretagogue. Rahmanian et al.
[4.25] reported the presence of two morphologically different types of cells in the equine
pituitary that both stained positive for prolactin; however, it is not known if both cell types
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secrete prolactin similarly in response to secretagogues or inhibitors. Potential differences in
functionality of subsets of lactotropes in horses warrants further study.
In summary, treatment with cabergoline suppressed prolactin for at least 4-5 days and
duration of prolactin suppression from administration of cabergoline was similar in spring and
summer. Given the naturally occurring low concentrations of prolactin in fall and winter, few
differences could be detected due to treatment. However, the October data were similar to those
reported by Arana Valencia et al. [4.9] for the fall, and could explain the discrepancies between
the data of Hebert et al. [4.8] and Arana Valencia et al. [4.9] relative to those of Oberhaus et al.
[4.10] in the spring. Low concentrations of prolactin in fall could explain the findings of Hebert
et al. [4.8] and Arana Valencia et al. [4.9] relative to those of Oberhaus et al. [4.10]. The
formulation of cabergoline in oil provided the same magnitude and duration of prolactin
suppression as did the cabergoline in a proprietary vehicle. In fact, other research (unpublished)
being conducted at Louisiana State University has described the same duration and magnitude of
prolactin suppression from intravenous administration of cabergoline in ethanol, intramuscular
administration of cabergoline in oil, and subcutaneous administration of cabergoline in vegetable
shortening. Given the potent and long-acting nature of cabergoline, the vehicle may not have an
enhancive effect on duration of suppression.
In conclusion, no seasonal variation was observed for the duration of suppression or the
degree of suppression of prolactin by a fixed dose of cabergoline. However, both sulpiride and
TRH-stimulated prolactin continued to be suppressed in cabergoline-treated mares long after
unstimulated prolactin concentrations had returned to normal. This apparent dichotomy may
indicate at least two subpopulations of lactotropes regulated differentially by dopaminergic input,
as has been reported in other species.
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CHAPTER 5: FACTORS AFFECTING THE OVARIAN RESPONSE TO A COMBINED
ESTRADIOL-SULPIRIDE TREATMENT IN SEASONALLY ANOVULATORY
MARES2
5.1 Summary
Twenty-three seasonally anovulatory mares, housed at two separate farms, were treated
with 50 mg of estradiol cypionate (ECP) and 3 g of sulpiride in January to study factors that
contributed to success of the treatment (response = ovulation within 28 days). Every-other-day
blood samples and pretreatment secretagogue challenges were used to characterize prolactin, LH,
IGF-I, leptin, and insulin concentrations. Ovaries of each mare were scanned via ultrasound
regularly until detection of a 32-35 mm follicle, at which time the mare was artificially
inseminated. Prolactin was stimulated in all treated mares and was similar (P > 0.05) in
responding and non-responding mares. Nine mares, all at the same farm (BH; farm effect, P =
0.006), responded with pre-ovulatory sized follicles within 20 days of treatment. Five of the 9
were inseminated and 3 conceived. Retrospective analysis revealed that of the mares responding,
body condition score (P = 0.03), body weight (P = 0.02), plasma concentrations of insulin (P =
0.01) and leptin (P = 0.09), and pretreatment response of LH to GnRH (P = 0.106) were higher in
responding than in non-responding mares. In general, factors that differed and may contribute to
whether a given mare responds to this ECP-sulpiride protocol were mainly characteristics
pointing towards well-nourished mares. Minor nutritional differences between farms likely
played a role in the lack of success on the one farm. Also, the LH response to GnRH prior to
treatment may be indicative of the subsequent LH response to ECP-sulpiride and hence the
ovarian response.
_________________
2

Reprinted with permission from the Journal of Equine Veterinary Science.
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5.2 Introduction
Treatment with exogenous prolactin or an induced increase in endogenous prolactin
concentrations can advance the first ovulation in seasonally anovulatory mares [5.1-5.5]. Nequin
et al. [5.1] hastened follicular growth in deep anestrous mares with one treatment of ovine
prolactin. Thompson et al. [5.2] advanced the date to first ovulation in pony mares in winter by
administration of recombinant porcine prolactin, although antibodies to the injected prolactin
were eventually detected in those mares. In lieu of exogenous prolactin, various dopaminergic
antagonists such as sulpiride [5.3, 5.5-5.7], domperidone [5.4], and fluphenazine [5.1] have been
used to stimulate secretion of endogenous prolactin. Sulpiride and domperidone have been used
most frequently to stimulate prolactin secretion, a response greatly enhanced by pretreatment
with estradiol [5.6-5.8], which was also shown to stimulate luteinizing hormone (LH) in
seasonally anovulatory mares [5.6].
In a series of experiments, Mitcham et al. [5.8-5.10] compared prolactin and ovarian
responses in mares receiving various doses of estradiol cypionate (ECP) combined with either
domperidone or sulpiride, generally at 1.5 or 3.0 g injected 1 to 11 days after ECP injection.
Throughout 10 years of experimentation, success rates (percentage of mares ovulating within a
specified period of time) have varied from a high of 89% [5.6] down to as low as 50% for the
more simplified protocols (treatment with ECP and one injection of sulpiride). In general, mares
that respond do so within 28 days. Non-responding mares typically ovulate much later,
interspersed with control mares. The question that arises after each experiment is why some
mares respond to the selected treatment, whereas others do not. That is, what factor(s), either
internal or external, affect(s) whether a mare responds or not?
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The aim of the current experiment was to describe and measure as many factors as
possible that could potentially affect the response of a given mare. Towards this end, all
available anovulatory mares were treated in January with a standard protocol of ECP followed by
a single injection of sulpiride, and pretreatment assessments as well as real-time hormonal data
were retrospectively used to determine any differences between mares that responded and those
that did not respond in the first 28 days. Because previous experiments had not assessed fertility
of early ovulations induced by ECP and sulpiride, responding mares were also artificially
inseminated with semen from a single stallion once a 32-mm or larger follicle was detected.
5.3 Materials and Methods
Procedures used in these experiments were approved by the Institutional Animal Care
and Use Committee of the Louisiana State University Agricultural Center.
5.3.1 Animals
Mares used in this experiment were housed at one of two Louisiana Agricultural
Experiment Station farms: the Central Research Station Horse Unit on the Ben Hur Plantation
(BH) and the Reproductive Biology Center (RBC). The two farms were located approximately 9
miles apart south of the Louisiana State University main campus in Baton Rouge. All mares were
maintained outdoors throughout the year. They grazed native grass pasture during the warmer
months and were supplemented with hay prepared from the same native grasses for ad libitum
consumption as needed in the fall and winter. In addition to this routine maintenance, mares at
the BH farm were also supplemented in winter with 18% protein tubs (Positive Feed, Ltd.; Sealy,
TX) and were limit-grazed on winter ryegrass pasture for 1 to 2 hours daily starting in January.
Starting in early December, 2015, all non-pregnant mares housed at the two farms were assessed
by ultrasonic scanning of the ovaries once a week, and samples of jugular blood were collected
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approximately weekly. Anovulation was defined as the absence of any follicle >20 mm, the
absence of any corpora lutea, and plasma progesterone concentrations consistently less than 1
ng/mL.
Twenty-three mares were identified that matched the criteria for anovulation: 14 from BH
and 9 from RBC. They were all light horse mares, mainly Quarter Horses, Thoroughbreds, and
Arabians with unknown reproductive history. Prior to the start of any treatments (first week of
January), body weight (BW) and body condition score (BCS; as described by Henneke et al.
[5.11]), were recorded for each mare.
5.3.2 Pretreatment Assessments, ECP-Sulpiride Treatment, and Blood Sampling
On January 9, 2016, all mares were challenged intravenously with a combination of
gonadotropin releasing hormone (GnRH; 0.5 µg/kg of BW) and sulpiride (racemic mixture; 4
µg/kg of BW) obtained from Sigma-Aldrich, St. Louis, MO. Samples of jugular blood were
drawn and 0, 10, 20 and 30 minutes relative to injection to characterize the LH, follicle
stimulating hormone (FSH), and prolactin responses. The blood samples were collected into 6mL evacuated tubes containing sodium heparin as an anticoagulant (Vacuette, Greiner Bio-One,
Monroe, NC). The following day (January 10, 2016), all mares received an intramuscular
injection in the neck of 50 mg of ECP (BET Pharm, LLC, Lexington, KY). This was considered
as day 0 of the experiment.
A comparison of timing of the sulpiride injection component of the standard protocol was
overlayed on the experiment, such that approximately half the mares at each farm received
sulpiride on day 1 (10 mares, 6 at BH and 4 at RBC) versus the rest that received sulpiride on
day 6 (13 mares, 8 at BH and 5 at RBC). Sulpiride injections consisted of 3 g of the racemic
mixture of sulpiride suspended in 5 mL of vegetable shortening (Crisco; J.M. Smucker
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Company, Orrville, OH) administered subcutaneously in the girth area as previously described
by Thompson et al. [5.12]. Jugular blood samples were drawn at 0, 1, 3, 6 and 24 hours relative
to injection of sulpiride, and then again every other day until February 28 (day 49). Plasma from
these samples was used for the determination of plasma prolactin, leptin, insulin, and insulin-like
growth factor-I (IGF-I) concentrations.
An additional jugular blood sample was collected from each mare on the day of ovulation
and again for 5 successive days thereafter for determination of plasma LH and progesterone
concentrations. For all blood samples collected throughout the experiment, plasma was harvested
by centrifugation at 1200 x g for 15 minutes and was stored at -20°C.
5.3.3 Ultrasonography and Artificial Insemination
An ovarian response was defined as the presence of a pre-ovulatory follicle at least 32
mm in diameter within 28 days after sulpiride injection, which either ovulated spontaneously or
was induced to ovulate with deslorelin. Ovarian follicular activity was monitored via
ultrasonography (Aloka 550V with 5-Mhz linear-array transducer; Hitachi-Aloka, Wallingford,
CT) every 3 to 4 days until a follicle 25 mm or greater was detected, after which the mare was
scanned daily until the follicle either reached 32 mm or greater, or regressed to < 25 mm. Upon
detection of a 32-mm follicle or greater, the mare was artificially inseminated with at least 500 x
106 progressively motile sperm from a stallion of proven fertility. After insemination, the mare
was administered 0.75 mg deslorelin (BET Pharm, Lexington, KY) intramuscularly to induce
ovulation. Inseminated mares were scanned for pregnancy at 12 days after ovulation. If an
embryonic vesicle was detected, the mare was scanned again at 16 and 22 days (+/- 1 day). Upon
detection of a heartbeat at 22 days or later, the pregnancy was terminated with a luteolytic dose
of dinoprost (Lutalyse; Zoetis Inc., Kalamazoo, MI). Some mares ovulated before obtaining a
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32-mm follicle, and were not inseminated. Those mares, plus inseminated mares that did not
conceive, were scanned every 3 to 4 days to determine their subsequent ovulation.
5.3.4 Hormonal Assays
Frozen plasma samples were thawed and analyzed for prolactin, FSH, LH, leptin, IGF-I,
insulin, and progesterone as appropriate. Prolactin, FSH, LH, leptin and IGF-I were measured
with radioimmunoassays previously validated by our laboratory [5.13-5.17]. Intra- and interassay
coefficients of variation and levels of detection were 7%, 12% and 0.2 ng/mL for prolactin; 6%,
9%, and 0.2 ng/mL for LH; 7%, 11%, and 1.4 ng/mL for FSH; 5%, 12%, and 8 ng/mL for IGF-I;
and 4%, 8%, and 0.8 ng/mL for leptin. Insulin and progesterone concentrations were measured
with commercially available kit reagents (ImmuChem Coated Tube 125I RIA Kit and ImmuChem
Double Antibody, 125I RIA Kit, respectively; MP Biomedicals, Costa Mesa, CA). The intra- and
interassay coefficients of variation and assay sensitivities were 5%, 8%, and 0.5 mIU/L for
insulin and 5%, 9%, and 0.05 ng/mL for progesterone. Estradiol was measured in acetoneextracted, 0.2 mL samples of plasma with commercially available kit reagents (MP Diagnostics
Estradiol 17-β Double Antibody, 125I RIA Kit); intra- and interassay coefficients of variation and
assay sensitivities were 7%, 12% and 1.2 pg/mL.
5.3.5 Statistical Analyses
Data for single-point dependent variables were analyzed by one-way analysis of variance
(ANOVA) using the general linear model of SAS (SAS Instit., Cary, NC). Ovarian response was
coded as 0 (no response) or 1 (response) for analysis (see below for treatment groups). Data for
dependent variables collected over multiple time points were analyzed by one-way ANOVA with
repeated sampling (split-plot design [5.4, 5.18]) with the same software. Retrospective analysis
showed that all mares responding with early ovulation were located at one farm (BH). Because

59

of the lack of success at RBC, analysis as a 2 x 2 factorial (with farm and success as the two
factors) was not possible, thus the treatments in the ANOVA were BH responding mares (BHR),
BH non-responding mares (BHN), and RBC non-responding mares (RBCN) run individually.
Subsequently, although there were no mares responding at RBC to the original ECP-sulpiride
treatment, there were 3 mares that displayed more ovarian activity than the rest of the RBC
mares, and came close to, but did not achieve, the 32-mm follicle size for breeding. Thus, these
mares were lumped together into a fourth treatment group as RBC transitional (RBCT) for
analyses of endpoints that might affect success.
All dependent variables were subsequently re-analyzed with the 4 groups in the main
analyses (treatments), as well as the timing of sulpiride (1 versus 6 days after ECP) and its
interaction with treatment. Time (minutes for the challenges, days for other hormonal
characteristics) was included as the repeated factor as appropriate. One-degree of freedom
contrasts [5.4, 5.18] were used to assess the effect of farm (BHN+BHR versus RBCN+RBCT)
and the difference between responding and non-responding mares at BH (BHN versus BHR) and
between the two groupings at RBC (RBCN versus RBCT). The mares within group interaction,
which tested treatment in the repeated measures ANOVA, was used as the error term for these
comparisons.
5.4 Results
5.4.1 Ovarian Responses and Pregnancies
An ovarian response was defined as the occurrence of a pre-ovulatory follicle at least 32
mm in diameter within 28 days after sulpiride injection, which either ovulated spontaneously or
was induced to ovulate with deslorelin. Of the 23 mares treated with ECP and sulpiride, 9
responded with early ovulation (Table 5.1). The average days to ovulation for those mares

60

Table 5.1. Number of horses treated at each farm that responded with
ovulation or a transition-like state.
Farm
Day of Sulpiride
No.
No. TransitionTreatment
n
Responding like
RBC
1
4
0 (0%)
1 (25%)
6
5
0 (0%)
2 (40%)
BH
1
6
5 (83%)
0 (0%)
6
8
4 (50%)
0 (0%)
Abbreviations: RBC, Reproductive Biology Center; BH, Ben Hur Farm.

responding was 11.7 +/- 1.0, and ranged from 7 to 18 days post-sulpiride injection. There was no
difference (P > 0.1) in days to ovulation between mares receiving sulpiride on day 1 versus 6
after ECP. Mares not responding to the ECP-sulpiride treatment were scanned weekly until midMarch; no ovulation was detected in any of these mares up to that point.
Of the 9 mares that responded to treatment, all 9 were residents of the BH farm. At RBC,
there were 3 mares that grew follicles up to 28 to 30 mm without ovulation. Given that these
were the only mares at RBC to show any ovarian response (albeit below threshold), they were readministered a second injection of sulpiride (same dose as previous) on day 42 (February 22) to
determine if perhaps a potentiation had been induced that might lead to a quick response. They
indeed responded with ovulatory sized follicles 12, 13, and 16 days after that second sulpiride
treatment. Given that these mares stood out from the rest of the mares at RBC, they were placed
in a separate group of their own (RBCT) for further analyses.
In the ANOVA for ovarian response, the RBCT mares were included as non-responding,
given that they did not ovulate within the original 28-day period. Accordingly, there were only
three treatment groups and no orthogonal contrast for RBCN versus RBCT. In that analysis,
there was an effect (P = 0.0059) of farm but no effect (P > 0.1) of day of sulpiride injection nor
any interaction with treatment.
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Of the 9 BH mares responding to treatment, 5 were artificially inseminated and induced
to ovulate with deslorelin, while the remaining 4 ovulated on their own without insemination or
deslorelin treatment. Of the 5 that were bred, 3 conceived and carried a pregnancy to 22 days, at
which time the pregnancy was terminated. All pregnancies had morphologically normal
embryonic vesicles and formation of embryo proper with cardiac activity. The 3 additional mares
that received a second sulpiride treatment (RBCT group) were also treated with deslorelin and
inseminated, and all 3 became pregnant, again with normal embryonic vesicles and cardiac
activity. Thus, the overall pregnancy rate was 6 of 8 mares that were inseminated, or 75%.
5.4.2 Characteristics of Responding and Non-responding Mares
Mean body condition scores, ages, and BW are presented in Table 5.2. The BHR mares
had a higher BCS (P = 0.06) than the non-responding mares at both farms, but did not differ
from RBCT mares. Age and weight were not different overall; however, contrast analyses (Table
5.3) indicated that BHR mares had higher BCS (P = 0.03) and weighed more (P = 0.02) than
BHN mares.

Table 5.2. Mean body condition score (BCS), age, and body weight for horses of
the four response groups at the two farms.
Treatment
Means
effect
BHN
BHR
RBCN
RBCT
P-value
BCS (1-9)
5.2a
6.5b
5.2a
5.3a,b
0.06
Age (yrs)
11
15
11
13
0.23
Weight (kg) 420.6
488.9
478.5
478.0
0.11
Abbreviations: BHN, Ben Hur non-responders; BHR, Ben Hur responders; RBCN, RBC
non- responders; RBCT, RBC transition-like.
a,b
Means within rows with no like superscript differ (P < .05).
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Table 5.3. One-degree of freedom contrast analyses for body condition
score (BCS), age, and body weight between farms and within farms.
P-value
Between
Farms

BHN vs.
BHR

RBCN vs.
RBCT

BCS

0.25

0.03

0.84

Age

0.56

0.11

0.44

Weight

0.30

0.02

0.99

Abbreviations: BHN, Ben Hur non-responders; BHR, Ben Hur responders;
RBCN, RBC non-responders; RBCT, RBC transition-like.

Prior to ECP treatment, FSH and prolactin responses to the GnRH and sulpiride
challenges were not different (P > 0.1; Figure 5.1) across the four groups of mares. Averaged
over the three post-GnRH sampling periods, mean concentrations of LH tended to be higher (P =
0.105; Figure 5.1) in BHR mares than in BHN mares.
Mean prolactin concentrations in every-other-day samples before and after treatment with
ECP plus sulpiride are presented in Figure 5.2. Because there was no effect (P > 0.1) of day of
sulpiride treatment on ovarian response, the data for all mares were normalized to day of
sulpiride treatment (rather than ECP injection). Overall, there was no effect (P > 0.1) of farm, no
difference between responding and non-responding mares at BH, and no difference between
mares in the RBCN and RBCT groups.
Mean plasma LH concentrations before ECP treatment and over the next 18 days are
presented in Figure 5.3. A significant effect of treatment (P = 0.004) and an interaction (P <
0.0001) between response and day were present between responding, non-responding, and RBCT
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Fig. 5.1. Plasma luteinizing hormone (LH), follicle stimulating hormone (FSH), and prolactin
areas under the curve after intravenous injection of gonadotropin releasing hormone and
sulpiride 24 hours before ECP injections. The farm-response groups were: mares at the Ben Hur
farm that did not respond (BHN), those that did respond (BHR), and mares at the Reproductive
Biology Center farm that did not respond (RBCN) and those that showed transitional-like
ovarian activity (RBCT). Number of mares per group were 5, 9, 6, and 3, respectively, for the
BHN, BHR, RBCN, and RBCT groups. a,bMeans for LH areas tended to differ (P = 0.105). Error
variances from the analyses of variance were 0.096, 1218, and 287 for LH, FSH, and prolactin,
respectively. The individual standard error of the means are shown by vertical lines within bars.

Fig. 5.2. Mean plasma concentrations of prolactin in response to subcutaneous sulpiride
injections in January (day 0). The farm-response groups were: mares at the Ben Hur farm that
did not respond (BHN), those that did respond (BHR), and mares at the Reproductive Biology
Center farm that did not respond (RBCN) and those that showed transitional-like ovarian activity
(RBCT). Number of mares per group were 5, 9, 6, and 3, respectively, for the BHN, BHR,
RBCN, and RBCT groups. No differences (P > 0.05) were detected between any of the four
groups of mares. Pooled standard errors of the means from the analysis of variance were 7.38,
5.5, 6.73, and 9.52 ng/mL, respectively.
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Fig. 5.3. Mean plasma concentrations of LH before ECP treatment (day 0) and over the next 18
days in Ben Hur responding mares (BHR), Ben Hur non-responding mares (BHN), RBC nonresponding mares (RBCN), and RBC transitional mares (RBCT). A significant effect of group (P
= 0.004) and an interaction (P < 0.0001) between group and day were present between
responding, non-responding, and transitional mares, with LH concentrations being greater in
BHR mares on days 10, 12, 14, 16, and 18 post ECP. Luteinizing hormone concentrations were
also greater (P < 0.05) in BHN mares than in RBCN or RBCT mares on days 14, 16 and 18 post
ECP treatment. Pooled standard errors of the means from the analysis of variance were 0.54,
0.41, 0.5, and 0.7 ng/mL, respectively. Asterisks (*) indicate differences between BHR and all
other groups; double daggers (‡) indicate differences between BHN and all other groups.

mares, with LH concentrations being greatest in BHR mares on days 10, 12, 14, 16 and 18 after
ECP. Luteinizing hormone concentrations were also greater (P < 0.05) in BHN mares than in
RBCN or RBCT mares on days 14, 16 and 18 post ECP treatment.
Plasma estradiol concentrations after treatment with ECP were measured in BH mares
only, given that no RBC mare ovulated within 28 days. There was no difference (P > 0.1) in
plasma estradiol concentrations between the responding and non-responding mares at BH
(Figure 5.4). Plasma estradiol peaked 1 to 2 days post ECP treatment and started a slow decline
through day 16 after ECP.
Means for plasma IGF-I, leptin, and insulin concentrations are presented in Table 5.4.
Concentrations of IGF-I did not differ (P > 0.1) among the four groups, nor was there any effect
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Fig. 5.4. Mean plasma estradiol concentrations in mares at the Ben Hur farm after treatment with
50 mg of ECP on day 0. Estradiol concentrations in mares at the Reproductive Biology Center
farm were not assessed given that no mare responded on that farm with a 32-mm or greater
follicle within 28 days. Pooled standard error of the mean from the analysis of variance was 2.13
pg/mL.

of farm. There was an effect of treatment (P = 0.01) on leptin concentrations as well as an
interaction between treatment and day (P < 0.0001). Leptin concentrations were highest in RBCT
mares; however, the difference was due primarily to two of the mares in particular with higher
than normal leptin concentrations. Contrast analyses (Table 5.5) revealed that leptin

Table 5.4. Mean plasma concentrations of IGF-I, leptin and insulin.
Treatment
effect

Mean (± SEM) plasma concentration, (ng/mL)
Hormone
IGF-I

BHN
138.4 ± 4.8

BHR
172.2 ± 3.5

RBCN
84.97 ± 4.3

RBCT
127.25 ± 6.0 0.16

Leptin

0.24 ± .04a

0.87 ± .03b

0.40 ± .04a,b

1.85 ± .05 c

Insulin

21.73 ± 2.1

a

36.62 ± 1.6

b

30.18 ± 1.9

a,b

37.08 ± 2.7

b

Interaction
with day

P-value
0.91

0.01

< 0.0001

0.05

0.33

Abbreviations: BHN, Ben Hur non-responders; BHR, Ben Hur responders; RBCN, RBC nonresponders; RBCT, RBC transition-like.
a-c
Means within rows with no like superscript differ (P < 0.05).
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concentrations were higher (P = 0.09) in the BHR mares than in the BHN mares, and were higher
(P = 0.003) in the RBCT mares than in the RBCN mares. There was also an effect of treatment
on insulin concentrations (P = 0.05), which were highest in RBCT and in BHR mares. Contrast
analyses (Table 5.5) showed that concentrations of insulin were higher (P = 0.01) in BHR mares
than in BHN mares.
Of the 9 mares responding at the BH farm, 5 were induced to ovulate with deslorelin
while the remaining 4 ovulated normally without deslorelin. All mares that responded with
ovulation experienced a normal rise in progesterone and decline in LH immediately following
ovulation (Figure 5.5). There was no difference (P > 0.1) between mares that were induced to
ovulate with deslorelin and inseminated and mares that ovulated spontaneously and were not
inseminated, indicating that addition of deslorelin provided no advantage over no treatment with
deslorelin.

Table 5.5. One-degree of freedom contrast analyses for plasma
IGF-I, leptin, and insulin concentrations between farms and within
farms.
P-value for contrast

IGF-I

Between
Farms
0.14

BHN vs.
BHR
0.42

RBCN vs.
RBCT
0.40

Leptin

0.06

0.09

0.003

Insulin

0.29

0.01

0.29

Hormone

Abbreviations: BHN, Ben Hur nonresponders; BHR, Ben Hur responders;
IGF-I, insulin-like growth factor-I; RBCN, RBC nonresponders; RBCT, RBC
transition like.
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Fig. 5.5. Mean plasma LH and progesterone concentrations on day of ovulation (day 0) and for 5
successive days after. No differences existed (P > 0.1) between mares that were induced to
ovulate with deslorelin and inseminated and mares that ovulated spontaneously and were not
inseminated. Pooled standard errors of the means from the analysis of variance were 1.7 ng/mL
for LH and 0.99 ng/mL for progesterone.

5.5 Discussion
The use of dopamine antagonist protocols to induce early ovulation in mares has met with
varying results. Some mares respond similarly from season to season, while others either never
respond or will respond one season, but not the next (E.L. Oberhaus, personal observation). The
aim of this study was to retrospectively analyze factors that might contribute to or prevent a mare
from responding to ECP and sulpiride with early follicular activity and ovulation. Also, while
dopamine antagonist protocols to induce ovulation have repeatedly been studied in our lab and
by others, it has not been determined whether ovulations induced by ECP-sulpiride are indeed
fertile and whether the uterus would support early pregnancy.
In this study, all mares were treated with ECP and a single subcutaneous injection of
sulpiride in vegetable shortening. Simultaneous controls (no treatment) were not included for
two reasons: 1) in order to analyze factors affecting success, we wanted as many mares as
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possible involved in the treatment to maximize the number and potential diversity of the group,
and 2) after 33 years of similar experimentation [5.2, 5.6-5.10, 5.19-5.23, 5.25], mares at the
LSU AgCenter farms that have been selected as anovulatory by the criteria described herein and
have served as controls have ovulated spontaneously in January or February only infrequently
(between 0 and 11%, depending on year), and typically begin ovulating in mid-march or later,
with an overall mean date of April 1. Experimental reduction in BCS, as described by Gentry et
al [5.25], extended the period of anovulation well into late April and May. In contrast to mares
selected as anovulatory, a certain percentage of mares on these same farms will have significant
follicular activity throughout the winter, and a few will continue to experience regular estrous
cycles.
Ten mares received sulpiride 1 day after ECP while 13 received sulpiride 6 days after
ECP. Mitcham et al. [5.8] observed a tendency for prolactin response to be higher in mares
receiving domperidone 1 day after ECP versus 6 days after ECP; however, in the present study,
day of sulpiride treatment did not affect the degree to which prolactin concentrations were
increased. Kelley et al [5.6] did not start sulpiride treatment until 10 days after the initiation of
estradiol injections. It is apparent from the results of all of our experiments combined that
considerable leeway exists for the period between ECP injection and sulpiride injection. Whether
simultaneous ECP and sulpiride injections would produce similar success rates needs to be tested
in the field.
Ovarian success, as defined by ovulation within 28 days post sulpiride treatment, was
relatively low in this experiment (9 of 23 mares, or 39%), whereas all 9 responding mares were
housed at one farm. Considering only mares at the BH farm, success was 9 of 14 mares, or 64%.
Success rates of 50 to 89% have been achieved in previous experiments [5.6-5.10], depending
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upon the specific protocol used. The 89% success rate of Kelley et al. [5.6] was based on everyother-day injections of estradiol benzoate followed by daily sulpiride injections started 11 days
later. Attempts to simplify that protocol into a single or double injection regimen is what has led
to the lower percentages of success. In the last experiment reported by Mitcham [5.10], a single
injection of ECP followed by three injections of sulpiride 5 days apart resulted in a success rate
of 77%. Reducing the number of sulpiride injections to two, 5 days apart, produced a success
rate of 63% (E.L. Oberhaus, personal observation). For the present experiment, the number of
sulpiride injections was reduced to one in an effort to simplify the protocol even further.
Pre-trial assessments of the LH, FSH, and prolactin responses to a standardized GnRHsulpiride challenge revealed no predictive information regarding FSH or prolactin responses
prior to ECP-sulpiride treatment. There was a tendency for a difference in LH response. The
tendency for a greater LH response to GnRH in BHR compared to BHN and RBCN may indicate
that the adenohypophyses of mares that would go on to respond to treatment were already more
competent in terms of LH synthesis and release, albeit low at that time of year. Given that no
mares had ovarian follicle(s) greater than 15 mm before the experiment started, all mares were
considered to be in a relatively “deep” anestrous-anovulatory state. This tendency of higher LH
response was evident in the responses to ECP injection, with the BHR mares having a much
greater rise in LH concentrations 10 to 18 days after ECP relative to BHN mares. The almost
total lack of LH response to ECP in the mares at RBC may account for the lack (or relative lack)
of ovarian stimulation.
Prolactin was stimulated in all mares for approximately 7 days by the injection of 3 g of
sulpiride in vegetable shortening. The response to sulpiride did not differ between mares that
ovulated early and mares that did not, nor did it differ between the two farms. An important point
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is that the responses were robust, with little variation, in contrast to what was often observed
with domperidone injections in previous experiments [5.7-5.9]. Thus, if there is indeed a
threshold level of prolactin concentrations that must be achieved for ovarian success, then it is
likely that all mares at both farms reached that threshold, whereas only mares at BH had
sufficient LH response to ECP to reach an ovulatory state. Previous injections of ECP alone,
with no dopaminergic antagonist to stimulate prolactin secretion, did not produce successful
ovarian responses [5.10]. In all our previous experiments with the estrogen-dopaminergic
antagonist combination, it has been consistent that both the prolactin response and the LH
response to estrogen must occur to some extent for the ovaries to respond. Failure of either
results in zero success.
It is well documented that nutrition and body condition play an important role in
reproduction [5.24-5.27]. Gentry et al. [5.25] demonstrated that low BCS of 3.0 to 3.5, produced
by nutrient restriction, resulted in low plasma leptin and IGF-I concentrations, low unstimulated
prolactin concentrations, a low LH response to GnRH, and an extended seasonal period of
anovulation with minimal follicular activity. Similarly, Guillaume et al. [5.26] observed an
increase in winter ovarian inactivity in feed-restricted pony mares, although to a lesser degree
than observed by Gentry et al. [5.25]. Interestingly, the prolactin response to sulpiride reported
by Gentry et al. [5.25] did not differ between high and low BCS mares, much like that observed
in the present experiment. Albeit speculation, parallels can be seen between the differences
observed herein between responding and non-responding mares, and the results of Gentry et al.
[5.25]: low BW and BCS, low plasma leptin, low LH response to GnRH, and in this experiment,
low insulin concentrations.
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In this experiment, plasma IGF-I concentrations did not differ between groups of mares,
but leptin and insulin were higher in the BHR than in the BHN mares even prior to treatment
with ECP and sulpiride. These hormones are generally thought of as indicators of nutritional
status, with higher concentrations associated with better nutrition. For mares housed at the BH
farm, the differences would be consistent with that concept. For the RBC mares, the trends are in
the same direction, but did not meet statistical muster. Due to different winter management
schemes at the two farms, differences in nutritional availability were present, even though all
mares were housed on pasture without any grain supplementation. Retrospective investigation
revealed that the mares at the BH farm had access to round bales of Alicia bermuda grass hay,
winter ryegrass pasture, and ad libitum protein tubs (primarily cottonseed and soybean meals,
molasses, and added vitamin A). Mares at the RBC farm had access to round bales of coastal
bermuda and rye grass hay, but did not have access to winter ryegrass or protein
supplementation. These differences in potential nutrient intake may have contributed to the
failure of RBC mares to respond to the initial treatment.
The three RBC mares that were considered transitional due to significant follicular
activity (relative to the other nonresponding mares) with no ovulation had the highest leptin
concentrations of all mares in the four groups. Of those three mares, two had leptin
concentrations ranging from 2 to 5.5 ng/mL compared to < 2 ng/mL for most other mares at both
farms. It is possible that these mares were hyperleptinemic as a result of insulin insensitivity
[5.16, 5.28], although no direct assessment of insulin sensitivity was performed. This is
somewhat contradictory to the findings of Ferreira-Dias et al. [5.27] where mares that continued
to cycle through the winter displayed leptin concentrations as high as 8 ng/mL with no reported
perturbations in cyclicity. Hyperleptinemia is typically associated with hyperinsulinemia, due to

72

compensated insulin resistance [5.16, 5.28]. However, the mean insulin concentrations in these
three mares were not outstanding relative to the other mares at both farms. Insulin insensitivity
per se is known to be associated with perturbations in estrous cyclicity [5.29, 5.30], thus studies
involving the use of sulpiride in these mares deserve further research. The fact that these three
mares responded so consistently and quickly to the second sulpiride injection on February 22
may indicate that the first ECP-sulpiride treatment established conditions within the ovaries that
potentiated the response to subsequent elevated prolactin concentrations.
The effect of ECP and sulpiride on LH concentrations seems to be somewhat complex.
Clearly, estradiol has a stimulatory effect on LH secretion, and an increase in LH has not been
observed in mares receiving a dopamine antagonist alone [5.6-5.10]. Garcia and Ginther [5.31]
administered 1 mg of estradiol daily to ovariectomized pony mares in February and observed an
increase in LH, but not until 6 days after initiation of treatment. Similarly, Kelley et al. [5.6] and
Mitcham [5.10] administered 11 mg estradiol benzoate and 150 mg ECP, respectively, to
seasonally anovulatory mares and did not observe an increase in LH until after treatment with
sulpiride 6 to 11 days after estrogen treatment. Moreover, Mitcham [5.10] administered sulpiride
or domperidone in biodegradable microparticles to mares simultaneously (same morning) as the
ECP injection and observed no increase in plasma LH concentrations over the next 21 days. The
question arises as to whether treatment with sulpiride after ECP enhances the LH response. In the
present study, an increase in LH was not observed until 10 days after ECP treatment. At that
point, concentrations of LH rose to levels similar to those seen around a typical, breeding season
ovulation, and appeared to coincide with late stage follicular growth and ovulation in those
(BHR) mares. Plasma estradiol in responding and non-responding mares at BH peaked one and
two days, respectively, after ECP treatment and then began to decline. Four of the 9 responding
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mares exhibited a decline in circulating estradiol followed by a subsequent rise around the time
of each mare’s respective ovulation; therefore, it is possible that LH is being stimulated by
endogenous follicular estradiol as well as the exogenous ECP.
Mari et al. [5.5] and Panzani et al. [5.32] assessed fertility following sulpiride treatment
in anestrous mares. First ovulation of the season was advanced in sulpiride-treated mares and
pregnancy rates on the first cycle were 40% (4/10) in one study [5.5] and 63.6% (14/22) in
another [5.32]. In addition, Mari et al. [5.5] reported normal foalings in all pregnant mares.
Throughout the series of experiments with estrogen pretreatment coupled with antidopaminergic
agents that we have completed [5.6-5.10], this is the first time to test the actual fertility of the
ovulations induced by treatment. Although minimal in number, the percentage of mares
becoming pregnant after insemination is certainly within the expected range for mares bred on
one estrous cycle in spring and summer. More extensive studies are needed to confirm whether
the fertility of these induced ovulations is indeed equivalent to later breedings. However, these
data are encouraging for breeders who want to get their open mares pregnant early in the year.
In conclusion, treatment with 50 mg of ECP followed by 3 g of +/- sulpiride in vegetable
shortening 1 or 6 days later elevated plasma prolactin concentrations in all mares for 6 to 8 days.
Given the robust responses across all mares, prolactin response could not be a factor in
determining whether a mare responded within 28 days or not (success). Assessments of plasma
FSH and prolactin responses to low-dose sulpiride and GnRH challenges provided no predictive
information as to future success. The tendency for higher LH response to GnRH in responding
mares prior to treatment may be indicative of the subsequent LH response and eventually the
ovarian response to ECP-sulpiride. Success was influenced by body condition and likely
nutritional status as indicated by higher plasma leptin and insulin concentrations in the
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responding mares. We suspect that the likelihood of a seasonally anovulatory mare responding to
the treatment protocol used herein is inversely correlated to the “depth” of the anestrous state.
That depth of anestrus is known to be influenced by nutritional status as well as proximity to the
seasonal transition period, as we [5.25] and others [5.33] have suggested in previous reports for
mares treated with only dopaminergic antagonists. Finally, from the limited inseminations
performed with these mares, we suspect that these induced ovulations are indeed fertile and can
produce at least 22-day embryos with heartbeats. Future research would be needed to better
clarify the actual fertility rate and to confirm that the pregnancies can be carried to term.
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CHAPTER 6: EFFECTS OF COMBINED ESTRADIOL-SULPIRIDE TREATMENT
AND FOLLICLE ABLATION ON VERNAL TRANSITION IN MARES: EVALUATION
OF PLASMA AND FOLLICULAR FLUID HORMONES AND LH RECEPTOR GENE
EXPRESSION
6.1 Summary
This experiment was designed to assess the hormonal production, secretory aspects, and
changes in LH receptor gene expression of early-induced ovulatory-sized follicles relative to the
first ovulatory sized follicles occurring naturally in the spring. Seasonally anovulatory mares
were treated on January 21 with 1) 50 mg estradiol cypionate (ECP, n = 8) alone or 2) with ECP
on January 21 followed by 2 sulpiride injections (3 g, s.q., in vegetable shortening, n = 8) 5 and
12 days later. Half of each group also received complete follicle ablation via transvaginal
aspiration prior to ECP treatment. Ovaries were scanned via ultrasonography regularly until
detection of a 32-35 mm follicle; follicular fluid was then recovered via aspiration and analyzed
for prolactin, estradiol and progesterone concentrations. Blood was collected every 4 days to
characterize plasma prolactin, LH, FSH, and estradiol concentrations. Also, on the day of
aspiration and for 6 more days, jugular blood was collected to characterize LH and progesterone
concentrations. Mean date to first 35-mm follicle was advanced (P < .05) in sulpiride-treated
mares: 5 of the 8 (63%) responded within 28 days of the first sulpiride treatment. Complete
follicle ablation did not affect (P > .1) the ovarian response. Plasma prolactin was stimulated (P
< .0001) in ECP-sulpiride treated mares for 16 days. There was no difference (P > .1) in plasma
prolactin in mares that responded with a large follicle versus mares that did not. Estradiol
treatment stimulated plasma LH in all mares (P < .05) and ablation did not affect (P > .1) LH
response to ECP. Plasma LH was higher (P < .05) in treated mares that responded compared to
mares that did not respond on days 8 and 12 after sulpiride treatment. In plasma samples
collected daily after aspiration, both LH and progesterone were higher (P < .01) in mares that
79

were treated with ECP-sulpiride and were not ablated compared to ECP-only treated mares (both
ablated and not) and to ECP-sulpiride treated mares that were ablated. Plasma estradiol was
similar (P > .1) in all mares on day of aspiration. There was a tendency for an increase in
follicular fluid prolactin in sulpiride-treated mares. There was no effect (P > .1) of treatment or
ablation on follicular fluid concentrations of estradiol, progesterone, leptin, or IGF-1, or on LH
receptor gene expression. In conclusion, combined ECP-sulpiride treatment stimulated
circulating prolactin and hastened the date to first pre-ovulatory follicle, but degree of prolactin
response was not a predictor of ovarian response. Sulpiride-treated mares that were not ablated
had elevated plasma progesterone and LH after aspiration. Ablation may inhibit maturity of the
first pre-ovulatory follicle based on decreased progesterone and LH production, but does not
inhibit growth and development of the first pre-ovulatory follicle.
6.2 Introduction
Stimulation of prolactin, either through administration of exogenous prolactin or via
administration of dopaminergic antagonists, has been shown to stimulate ovarian follicular
growth and hasten the date to first ovulation in seasonally anovulatory mares [6.1-6.5]. Nequin et
al. [6.1] hastened follicular growth in seasonally anestrous mares with one treatment of ovine
prolactin. Similarly, Thompson et al. [6.2] administered recombinant porcine prolactin to winter
anestrous pony mares and advanced the first ovulation of year. Sulpiride and domperidone have
been used most frequently to stimulate prolactin secretion, a response greatly enhanced by
pretreatment with estradiol [6.6-6.11], which was also shown to stimulate luteinizing hormone
(LH) in seasonally anovulatory mares [6.6, 6.11]
The exact mechanism by which prolactin stimulates follicular growth in seasonally
anovulatory mares has yet to be identified. Receptors for prolactin have been localized on
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equine ovarian follicular cells [6.12] as well as luteal cells [6.13], which is an indication that
prolactin can exert its action directly on the ovarian follicle. Prolactin has an obligatory role in
ovarian function in several species, such as formation and maintenance of the corpus luteum
(CL; [6.14, 6.15]). It has also been suggested that prolactin is responsible for inducing functional
LH receptors on granulosa cells and CL of rats as well as sustaining progesterone secretion from
the CL [6.16-6.18]. Richards and Williams [6.16] and Holt et al. [6.17] observed an enhancive
effect of prolactin on LH receptor content and progesterone production, but not a direct effect of
prolactin alone. Conversely, Bjurulf et al. [6.18] observed a ten-fold increase in LH receptor
messenger mRNA in luteal cells of prolactin-treated rats as well as an increase in circulating
progesterone concentrations when compared to controls. Furthermore, a marked decrease in LH
receptor mRNA was detected in prolactin receptor null mutant mice [6.19]. This effect of
prolactin on LH receptors and receptor mRNA in females is directly analogous to the complete
requirement for prolactin for spermatogenesis in the male hamster [6.20, 6.21], which was shown
to be mediated by prolactin’s necessity for LH receptors on hamster Leydig cells [6.22].
In the mare, a local role for prolactin in the ovary has been proposed due to the
remarkable and rapid growth of ovarian follicles in response to either exogenous prolactin or
indirectly through treatment with dopaminergic antagonists in the winter. Exactly how
exogenous or endogenously stimulated prolactin facilitates early follicular growth has yet to be
determined. Therefore, the aim of this study was to induce early follicular growth in seasonally
anestrous mares with treatment of ECP and subsequently sulpiride as described by Mitcham et
al. [6.10] and Oberhaus et al. [6.11] and assess changes in ovarian follicle hormone production
and LH receptor content. The effect of complete follicle ablation prior to treatment was also
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assessed to determine if the induction of a new follicular wave had an effect on the ovarian
response to treatment.
6.3 Materials and Methods
Procedures used in these experiments were approved by the Institutional Animal Care
and Use Committee of the Louisiana State University Agricultural Center.
6.3.1 Animals and Treatments
Mares used in this experiment were housed at one of two Louisiana Agricultural
Experiment Station farms: the Central Research Station Horse Unit on the Ben Hur Plantation
(BH) south of the LSU campus and the Reproductive Biology Center (RBC) located in St.
Gabriel, Louisiana. The two farms were located approximately 9 miles apart south of the
Louisiana State University main campus in Baton Rouge. All mares were maintained outdoors
throughout the year. They grazed native grass pasture during the warmer months and were
supplemented with hay prepared from the same native grasses for ad libitum consumption as
needed in the fall and winter.
Starting on December 29, 2014, all non-pregnant mares housed at the two farms were
assessed for 3 weeks by weekly ultrasonic scanning of the ovaries sampling of jugular blood.
Anovulation was defined as absence of a follicle > 20 mm in diameter on either ovary, absence
of any corpora lutea, and plasma progesterone concentrations consistently < 1 ng/mL.
Sixteen light horse, anovulatory mares were identified (8 at each farm) and were allotted
into two similar groups based on age (7 to 25 years old) and body condition score (4 to 7;
[6.23]). The groups were then randomly assigned to treatment (n = 8) or control (n = 8). Half of
each group was subjected to complete follicle ablation 5 days prior to sulpiride treatment.

82

On January 21, 2015, all mares received 50 mg estradiol cypionate (ECP, BET Pharm,
LLC, Lexington, KY), intramuscularly. Five days later, on January 26, mares allotted to the
combined treatment group (n = 8) received 3 g of sulpiride (racemic mixture; Sigma-Aldrich, St.
Louis, MO) dissolved in 5 mL of vegetable shortening (Crisco; J.M. Smucker Company,
Orrville, OH) administered subcutanesouly in the girth area as previously described by
Thompson et al. [6.24]. Control mares (n = 8) received 5 mL vegetable shortening only in the
girth area. All mares received a second sulpiride or control treatment of the same nature 7 days
later on February 2.
6.3.2 Blood Sampling
On January 21, 2016, just prior to treatment with ECP, jugular blood samples were
collected from each mare into to 6-mL evacuated tubes containing sodium heparin as an
anticoagulant (Vacuette, Greiner Bio-One, Monroe, NC). On January 26 (day 0), samples were
drawn at 0 min, 1, 3, 6, 12 and 24 hours relative to treatment with sulpiride or vehicle and
continued every four days until April 16 (day 80) to determine circulating plasma prolactin, LH,
FSH, and estradiol concentrations. Additionally, on the day of aspiration and for five successive
days after, a single blood sample was drawn to determine circulating concentrations of LH and
progesterone. Plasma was harvested from all samples in the experiment by centrifugation at 1200
x g for 15 minutes and was stored at -20°C.
6.3.3 Ultrasonography and Transvaginal Follicle Aspiration
On the day of ECP treatment (day -5), just prior to treatment, half of the mares in each
group received a complete follicle ablation which involved aspiration of all visible follicles on
each ovary prior to any treatment via the aspiration procedure described below. After treatment
with ECP, ovarian activity was monitored via ultrasonography (Aloka 550V with 5-Mhz linear-
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array transducer; Hitachi-Aloka, Wallingford, CT) every 3 to 4 days until a follicle(s) >25 mm
emerged. Upon detection of a follicle >25 mm, the mare was scanned daily until the follicle
either reached at least 35 mm or regressed to <25 mm. Once a 35-mm follicle was observed, the
follicle was aspirated.
For aspirations, including those during complete follicle ablation, each mare was
administered intravenous detomidine (.01 mg/kg BW; Dormosedan, Zoetis, Parsippany-Troy
Hills, NJ) for sedation and N-butylscopolammonium bromide (.25 mg/kg BW; Buscopan,
Boehringer Ingelheim Vetmedica, Inc, St. Joseph, MO) for rectal relaxation. Additional amounts
of these medications were administered as needed. A 5 MHz curvilinear probe housed in hard
plastic casing was used for visualization and aspiration. The follicle was aspirated with a 12gauge double lumen needle attached to a vacuum-pump at a pressure of -150 mmHg. The probe
was inserted transvaginally and placed directly against the vaginal wall. The ovary was then
manipulated transrectally such that the follicle was placed next to the end of the ultrasound
probe. A second technician advanced the needle through the vaginal wall and into the follicle.
The follicle was immediately evacuated of follicular fluid in to a sterile 50 mL conical tube; the
fluid was stored for later analysis of prolactin, estradiol, progesterone, IGF-1 and leptin. The
follicle was then flushed several times with Dulbecco’s phosphate buffered saline (PBS, SigmaAldrich, St. Louis, MO) supplemented with 10 U/mL heparin and 1.5% bovine calf serum
warmed to 38°C and the flushing fluid was evacuated into a sterile bottle. Upon collection of
follicle contents, cells were filtered to remove blood contamination, rinsed with PBS, and
manually pipetted into cryovials. Cells were centrifuged at 700 x g for 15 min and pellets
resuspended in RNAlater (Sigma-Aldrich, St. Louis, MO) and stored at -80°C until analysis.
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6.3.4 Radioimmunoassay
Frozen plasma samples were thawed and analyzed for prolactin, LH, FSH, progesterone
and estradiol as appropriate. Follicular fluid samples were analyzed for prolactin, progesterone,
estradiol, IGF-1 and leptin concentrations. Prolactin, LH, FSH, IGF-I, and leptin were measured
by radioimmunoassay in assays previously validated by our laboratory [6.25-6.29]. Intra- and
interassay coefficients of variation and levels of detection were 7%, 12% and 0.2 ng/mL for
prolactin; 6%, 9%, and 0.2 ng/mL for LH; and 7%, 11%, and 1.4 ng/mL for FSH; 5%, 12%, and
8 ng/mL for IGF-I; and 4%, 8%, and 0.8 ng/mL for leptin. Progesterone and ether-extracted
estradiol were analyzed using commercially available kit reagents (ImmuChem Progesterone
Double Antibody, 125I RIA Kit and 17β-Estradiol (E2) Double Antibody RIA Kit, MP
Biomedicals, Inc, Costa Mesa, CA). For estradiol determination in follicular fluid, samples were
diluted to a final concentration of 1:5000 before extraction with extracted with diethyl ether.
6.3.5 RNA Extraction and Q-PCR
Total RNA from cell aspirates was extracted using the RNeasy Micro Kit (Qiagen,
Valencia, CA) per manufacturer’s instructions. Complementary DNA (cDNA) was generated
using iScript Reverse Transcription Supermix (Bio-Rad, Hercules, CA). For each reverse
transcription reaction, total RNA was added to 4 µL reverse transcription supermix and nucleasefree water for a total volume of 20 µl per reaction. Reverse transcription was performed
following the manufacturer’s recommendations with 5 min at 25°C, 20 min at 46°C, and 1 min at
95°C.
Luteinizing hormone receptor (LHr) expression was determined by quantitative, real-time
PCR using the comparative cycle time method. This method measured the fold-change in mRNA
for LHr between samples normalized to a reference gene. The reference gene used in the present

85

study was glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which has previously been
used for mRNA semi-quantitation in similar protocols [6.30, 6.31]. Equine specific primers
were generated for LHr (Thermo Fisher Scientific, Waltham, MA; Table 6.1) and GAPDH
(Integrated DNA Technologies, Coralville, IA; Table 6.1). Primers for each gene were validated
on equine luteal tissue, testes, and ovarian follicle cell aspirates. The PCR products were
separated on 1% agarose gel and visualized with ethidium bromide.

Table 6.1 Genes of interest with primer sequences, accession numbers and amplicon length
Genes of
Forward primer
Reverse primer
GenBank
Amplicon
Interest
5’ – 3’
5’ – 3’
Accession No.
length
Luteinizing
hormone
acgacactgatttccctggag acagcagtggcttgggtaag
XM_005599992.2 252 bp
receptor
(LHr)
GAPDH

caggttgtctcctgcgattt

cataaggtccaccaccctattg

NM_001163856.1 147 bp

Quantitative, real-time PCR was performed using commercially available reagents
(SsoFast EvaGreen Supermix, Bio-Rad Laboratories, Hercules, CA) and analyzed on the CFX
Connect Real-Time System (BioRad, Hercules, CA). A positive control (calibrator) was
developed by combining mRNA from all control tissues and ovarian cell aspirates and
transforming to cDNA as previously described. When appropriate, calibrator cDNA was
“spiked” with purified PCR product (Monarch PCR & DNA Cleanup Kit, New England Biolabs,
Ipswich, MA) such that a final concentration of 2 pg/µL was achieved for target genes. Samples
were run in triplicate and consisted of 10 µL supermix, 1 µL each of forward and reverse
primers, 4 µL water, and 4 µL sample cDNA, calibrator cDNA, or water as negative control.
PCR amplifications consisted of 40 cycles of enzyme activation (95°C, 30 seconds), denaturation
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(95°C, 5 seconds), annealing (53°C, 5 seconds for GAPDH, 57°C, 5 seconds for LHr) and
extension (65°C, 5 sec). Melt curve analysis was performed on each sample to confirm
specificity of amplification. The PCR products were separated on 1% agarose gel and visualized
with ethidium bromide.
6.3.6 Data Analyses
Data for dependent variables collected over many different time points (plasma
concentrations of prolactin, LH, etc.) were analyzed by 2x2 factorial one-way analysis of
variance (ANOVA) with repeated sampling using the general linear model of SAS (SAS Instit.,
Cary, NC). Relative gene expression was calculated using 2-ΔΔCT [6.32]. Quantitative cycle
values were normalized against the reference value of the housekeeping gene (GAPDH) within
the same sample. These normalized values as well as follicular fluid factors and date to first
ovulation were then analyzed by 2x2 factorial one-way ANOVA. Effects of follicle ablation and
treatment were tested with animal within the interaction between follicle ablation and treatment
as the error term. When appropriate, differences between treatment groups within time periods
were tested for significance by the least significant difference test [6.33].
6.4 Results
An ovarian response was defined as the occurrence of a pre-ovulatory follicle at least 35
mm in diameter within 28 days after the first sulpiride injection, which was then aspirated via
ultrasound guided transvaginal aspiration. Complete follicle ablation had no effect (P > .1) on
many of the factors presented herein; therefore, when no effect was observed, means are
presented simply as treatment versus control. When complete follicle ablation did have an effect
(P < .05), means are presented for all four groups comprising the 2x2 factorial. Of the 8 mares
treated with ECP-sulpiride, 5 responded with early ovulatory sized follicles. Mean date to first
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35 mm follicle was advanced (P = .03) in mares treated with ECP-sulpiride (61 ± 10 days
compared to mares treated with ECP and vehicle only (96 ± 10 days). These days represent day
of the calendar year. There was an interaction (P < .0001) between treatment and day for mean
plasma prolactin concentrations in samples obtained every 4 days (Figure 6.1). Prolactin was
stimulated in sulpiride-treated mares for at least 12 days post treatment. No increase in prolactin
was observed in mares treated with ECP and vegetable shortening. No differences (P > .1) in the
prolactin response to sulpiride were found between mares that responded with an early

Figure 6.1 Mean concentrations of prolactin in samples obtained every four days in mares treated
with 50 mg ECP and 3 g sulpiride in vegetable shortening (ECP + Sulpiride) or mares treated
with 50 mg ECP and vegetable shortening only (Control). Sulpiride or vehicle was administered
on day 0 and on day 7. Asterisks indicated differences (P < .0001) between means at specified
time points. Pooled standard error was 3.5 ng/mL.

ovulatory sized follicle (35 mm) and mares that did not. Complete follicle ablation prior to
treatment with ECP-sulpiride had no effect (P > .1) on the prolactin response.
Estradiol cypionate stimulated plasma LH in all mares (P < .05; Figure 6.2A), with
concentrations being higher in ECP-sulpiride treated mares on day 12. Ablation had no effect (P
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> .1) on LH response to ECP. Plasma LH was higher (P < .05; Figure 6.2B) in treated mares that
responded compared to mares that did not respond on days 8 and 12 post sulpiride treatment.
Neither treatment nor ablation had an effect (P > .1) on circulating FSH in samples collected
every four days after treatment.
Concentrations of prolactin in follicular fluid aspirated from the first 35 mm follicle were
greater (P = .05) in mares treated with ECP-sulpiride compared to mares that received ECP and
vehicle only. There was also an interaction (P = .06, Figure 6.3) between treatment and ablation

Figure 6.2. Mean plasma concentrations of LH in mares treated with 50 mg ECP and 3 g
sulpiride in vegetable shortening (ECP + Sulpiride) or mares treated with 50 mg ECP and
vegetable shortening only (Control; Panel A), and ECP-sulpiride treated mares who responded
(Responders) with early ovulatory sized follicles compared to mares that did not (Nonresponders; Panel B). Asterisks indicate differences between means at specified periods. Pooled
SEM were 1.8 ng/mL for Panel A and 1.4 ng/mL for Panel B.
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with concentrations being higher in mares treated with ECP-sulpiride that did not receive
complete follicle ablation prior to treatment compared to treated mares that did. Follicular fluid
concentrations of prolactin, estradiol, progesterone, leptin and IGF-1 are presented in Table 6.2.
Except for prolactin, no differences (P > .1) were detected in the remaining hormones
between mares treated with ECP-sulpiride compared to mares that received ECP and vehicle
only. No effect of ablation (P > .1) was observed for these hormones either.

Figure 6.3 Mean concentrations of prolactin in follicular fluid aspirated from the first 35
mm follicle in mares treated with either ECP-sulpiride (T) or ECP and vehicle only (C) and
received a complete follicle ablation prior to treatment (Ablation) or did not (No Ablation).
Different letters indicate differences at P < .1. Pooled standard error of the mean was 7.3 ng/mL.

In plasma samples collected daily after aspiration, both LH and progesterone were higher
(P < .01, Figure 6.4) in mares that were treated with ECP-sulpiride and were not ablated
compared to ECP-only treated mares (both ablated and not) and to ECP-sulpiride treated mares
that were ablated. Plasma estradiol and FSH were similar (P > .1) in all aspirations.
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Table 6.2 Mean concentrations of prolactin, estradiol, progesterone, leptin and
IGF-1 in follicular fluid aspirated from the first 35 mm follicle.
Mean ± SEM follicular fluid concentration
Treatment effect
(ng/mL)
Control
ECP - Sulpiride
P – value
a
b
Prolactin
1.8 ± 4.5
15.2 ± 3.7
.05
a
a
Estradiol
742.2 ± 217.5
861.9 ± 177.6
.63
a
a
Progesterone
55.7 ± 30.9
121.3 ± 25.2
.13
a
a
Leptin
1.05 ± 0.8
0.94 ± 0.7
.91
a
a
IGF-1
166.6 ± 30.7
180 ± 33.7
.76
Control = 50 mg ECP followed by treatment with vegetable shortening;
ECP - Sulpiride = 50 mg ECP followed by treatment with 3 g sulpiride in vegetable
shortening. a-b Means within rows with no like superscript differ (P < .05).

Relative gene expression for LH receptors in cell aspirates from the first 35 mm or
greater follicle was similar (P > .1, Figure 6.5) between all mares (treated versus control and
ablation versus no ablation). Means for all four groups are shown to illustrate the consistency
among groups.
6.5 Discussion
To date, this is the first study to assess changes in ovarian follicular factors in response to
induced follicle growth after stimulation via prolactin elevation in winter. Ovarian success was
defined by ovulation within 28 days post sulpiride treatment. Success rates of 50 to 89% have
been achieved in previous experiments [6.6-6.10], depending upon the specific protocol used.
The 89% success rate of Kelley et al. [6.6] was based on every-other-day injections of estradiol
benzoate followed by daily sulpiride injections started 11 days later. A single injection of ECP
followed by three treatments with sulpiride 5 days apart resulted in a success rate of 77% [6.10].
A success rate of 39% was reported by Oberhaus et al. [6.11] with only a single treatment of
sulpiride either 1 or 5 days after ECP administration. In the current experiment, two sulpiride
injections, administered 7 days apart, produced a success rate of 63% (5/8).
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Figure 6.4 Mean plasma concentrations of LH (Panel A) and progesterone (Panel B) after
aspiration of the first 35 mm follicle in mares treated with either ECP-sulpiride (T) or ECP and
vehicle only (C) and received a complete follicle ablation prior to treatment (Ablation) or did not
(No Ablation). Asterisks indicate differences (P < .01) between specific time periods within
each panel. Pooled standard errors of the means were 1 ng/mL for LH and 0.34 ng/mL for
progesterone.

Figure 6.5 Relative gene expression for LH receptors after aspiration of the first 35 mm follicle
in mares treated with either ECP-sulpiride (T) or ECP and vehicle only (C) and received a
complete follicle ablation prior to treatment (Ablation) or did not (No Ablation). Like letters
indicate no differences (P > .1).
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Timing of sulpiride treatment relative to ECP treatment has been investigated in several
studies. Mitcham et al. [6.9] observed a tendency for prolactin response to be higher in mares
receiving domperidone 1 day after ECP versus 6 days after ECP, whereas Oberhaus et al. [6.11]
did not observe any differences in the prolactin response to sulpiride or the ovarian response
between mares receiving sulpiride 1 versus 5 days after ECP. To simplify treatment, all treated
mares in the present study received the first sulpiride injection 5 days after ECP. Timing of the
first sulpiride treatment relative to ECP treatment does not appear to affect the ovarian response;
however, a greater number of sulpiride treatments do appear to increase chances of a response.
Prolactin was stimulated in all sulpiride-treated mares for approximately 12 days by the
injection of 3 g of sulpiride in vegetable shortening. The response to sulpiride did not differ
between mares that developed 35 mm follicles early and mares that did not; moreover, treatment
with ECP alone did not stimulate prolactin and resulted in no ovarian response. A second
treatment of sulpiride 7 days after the first did not further increase prolactin in treated mares,
although it appeared to sustain elevated prolactin for a longer period. This is compared to the 7day stimulation of prolactin with one injection of sulpiride in a similar manner observed by
Oberhaus et al. [6.11]. Given higher success rates in the present study with two sulpiride
treatments versus one [6.11], it is likely that duration of prolactin stimulation, not magnitude, is
contributory to ovarian response, as long as the prolactin response is above a given threshold.
That is, a poor prolactin response is known to lead to no ovarian response.
All mares in this experiment were treated with 50 mg ECP; therefore, an increase in LH
was observed in sulpiride-treated mares as well as mares treated with vehicle. Given the limited
availability of seasonally anovulatory mares, it was decided that mares serving as controls would
receive ECP as well to separate out any compounding effects of the ECP-sulpiride combination.
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In past experiments [6.6, 6.10, 6.11], an increase in LH has not been observed in ECP or
estradiol benzoate-treated mares until after sulpiride treatment, which led to the speculation that
ECP and sulpiride, in combination, stimulate LH. In the present study, the LH response was
virtually identical in sulpiride- and vehicle-treated mares and only differed 12 days after
sulpiride treatment, which coincided with the first pre-ovulatory follicles that developed in 4 of
the responding mares. Concentrations of LH were elevated in sulpiride-treated mares responding
with a pre-ovulatory follicle compared to mares that did not 8 and 12 days after treatment with
sulpiride. Again, this coincided with late stage follicular growth in responding mares; therefore,
it is possible that LH is being stimulated by endogenous follicular estradiol as well as the
exogenous estradiol via ECP injection.
Concentrations of prolactin, estradiol, progesterone, leptin, and IGF-1 were measured in
follicular fluid collected from the first pre-ovulatory follicle in each mare. Prolactin was higher
in sulpiride-treated mares that were not ablated prior to treatment compared to sulpiride-treated
mares that were ablated and vehicle-treated mares both ablated and not. Two of the 5 responding
mares had extremely high (> 30 ng/mL) prolactin concentrations, which accounted for the
statistical significance. When those mares were removed from the analysis (for comparison), the
effects of treatment and ablation were no longer significant but there was still a tendency for
sulpiride-treated mares to have higher prolactin concentrations in follicular fluid.
Concentrations of prolactin in follicular fluid have been shown to increase with follicle
size in the mare and the rise in follicular fluid prolactin coincided with a surge in plasma
prolactin observed during the periovulatory period [6.34]. Although it is unclear if the rise in
plasma prolactin contributes to follicular fluid prolactin, it is likely that a robust prolactin
response to sulpiride is stimulatory to ovarian follicle prolactin production.

94

Estradiol and progesterone concentrations within the follicles were variable among
mares, but did not differ between mares that were treated with sulpiride and mares that received
vehicle only. Low estradiol and progesterone concentrations have been observed in follicular
fluid of seasonally transitional follicles [6.35], and it is current dogma that a deficiency in
steroidogenesis by the early transitional follicle is responsible for the prolonged presence of an
ovulatory-sized follicle that fails to ovulate [6.36]. Given that no difference was observed in
follicular fluid estradiol and progesterone between treated and control mares, it appears that
early-induced follicles are equally as competent in terms of steroid production as those occurring
naturally in the spring.
Concentration of IGF-1 was measured in fluid collected from the first pre-ovulatory
follicle due to its proposed role in initiating selection of the future dominant follicle [6.37, 6.38]
and association with steroidogenesis [6.39]. Leptin was measured due to its negative
relationship with reproduction in mares [6.40]. Both IGF-1 and leptin concentrations were
similar in follicular fluid collected from the first pre-ovulatory follicle of sulpiride and vehicletreated mares.
In daily plasma samples collected for 6 days after follicular aspiration, both LH and
progesterone concentrations were higher in responding mares that were treated with sulpiride and
not ablated prior to treatment than responding, sulpiride-treated mares that were ablated. Nonresponding mares were excluded from the analysis given that they developed pre-ovulatory
follicles outside the 28 day response period when prolactin was no longer stimulated. The goal
of the analysis was to characterize LH and progesterone immediately after aspiration of earlyinduced follicles compared to those occurring naturally. The significant rise in LH can be
attributed to one mare who had LH concentrations > 15 ng/mL. Excluding her from the analysis
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revealed a similar rise in LH immediately after aspiration, much like that reported by Hinrichs et
al. [6.41] and observed naturally after ovulation.
Plasma samples were collected daily after aspiration to determine if complete aspiration
of a pre-ovulatory follicle would lead to luteinization of the follicle and, subsequently,
progesterone production as has been previously reported in the mare [6.41, 6.42]. There was a
post-aspiration increase in plasma progesterone, similar to a rise in early diestrus, in mares that
responded and were not ablated prior to sulpiride treatment. Both mares in this group had a
similar rise in progesterone. Non-responding, sulpiride-treated mares that were ablated, as well
as vehicle-treated mares, both ablated and not, failed to produce progesterone concentrations > 1
ng/mL. For the 3 responding mares that were subjected to complete follicle ablation prior to
treatment, ablation took place 17 days (2 mares) and 23 days (1 mare) prior to aspiration of the
first pre-ovulatory follicle. Given the small number of responding mares in each group, these
results are tenuous; however, the question arises as to what effect follicle ablation prior to
treatment may have on the future of the next ovulatory follicle in terms of progesterone
production.
For those vehicle-treated mares assigned to complete follicle ablation, ablation took place
60 days prior to aspiration of the first pre-ovulatory follicle at the earliest. Similar
concentrations of follicular fluid progesterone in all groups of mares indicate similar
steroidogenic capabilities; however, both vehicle-treated groups of mares (ablated vs. not
ablated) failed to produce progesterone after aspiration of the first pre-ovulatory follicle. Since
the pre-ovulatory follicle was aspirated, it is not known if that follicle was going to ovulate and
form a fully functional CL. It is possible that the first naturally occurring, pre-ovulatory sized
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follicle would have been anovulatory, and thereby not equipped for complete formation of a
functional CL leading to insufficient plasma progesterone.
The most important factor contributing to a mare returning to cyclicity seems to involve
1) the re-establishment of LH secretion and its associated receptor [6.43] and 2) adequate plasma
prolactin concentrations that may affect the LH receptor content. The first ovulatory-sized
follicle of the season often grows to a diameter of > 40 mm before either regressing or eventually
ovulating several days, or sometimes weeks, later (EL Oberhaus, personal observations). This
led to the hypothesis that there is a failure of LH to induce ovulation either through insufficient
pituitary production (perhaps by absence of estradiol feedback) or through inability of LH to
exert its action on the ovarian follicle due to insufficient receptors. Given the stimulatory effects
of prolactin on LH receptors in other species [6.18-6.22], the hypothesis that sulpiride
upregulates LH receptors within the equine ovarian follicle was tested in this experiment.
Luteinizing hormone receptor content, as determined by Q-PCR, was similar in early sulpirideinduced follicles and in those naturally occurring later in the season in control mares. This likely
indicates that the early-induced, pre-ovulatory follicle can respond to circulating LH equally to
follicles occurring naturally but later in the spring. One of the limitations of this experiment was
the experimental paradigm only allowed for comparison of samples from ovarian follicles of like
sizes in treated and control animals, which were unlikely to be collected during the same time
period. In other words, a 35-mm follicle from a treated mare obtained in February would not
normally provide a logical comparison to a 35-mm follicle from a control mare obtained in April.
However, the data presented herein indicate that the treatment-induced, early follicles were
indeed equivalent to their later, naturally occurring counterparts. Thus, prolactin may in fact be
needed for the early-induced follicles to become LH responsive, and without it they would be
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unresponsive and would not grow to pre-ovulatory size (as seen in mares that do not have a
significant prolactin rise). What was not available for comparison was 35-mm or larger follicles
from untreated mares at the same time.
In conclusion, combined ECP-sulpiride treatment stimulated circulating prolactin and
hastened the date to first pre-ovulatory follicle, but degree of prolactin response was not a
predictor of ovarian response, likely because it was beyond adequate in all treated mares.
Sulpiride-treated mares that were not ablated had elevated plasma progesterone and LH after
aspiration. There was a tendency for an increase in follicular fluid prolactin in sulpiride-treated
mares. Ablation may inhibit maturity of the first pre-ovulatory follicle based on decreased
progesterone and LH production, but does not inhibit growth and development of the first preovulatory follicle. Most importantly, early-induced follicles appear to be equally mature
(competent) to those occurring naturally in the spring in terms of steroid production and LH
receptor mRNA. Because of this, ovulations from these induced follicles have in fact been shown
to be fertile to a degree similar to those occurring naturally later in the spring [6.11].
6.6 References
[6.1] Nequin LG, King SS, Johnson AL, Gow GM, Ferreira-Dias GM. Prolactin may play a
role in stimulating the equine ovary during the spring reproductive transition. J Equine Vet Sci
1993;13:631-5.
[6.2] Thompson DL, Hoffman R, DePew CL. Prolactin administration to seasonally anestrous
mares: Reproductive, metabolic, and hair shedding responses. J Anim Sci 1997;75:1092–9.
[6.3] Besognet B, Hansen BS, Daels PF. Induction of reproductive function in anestrous mares
using a dopamine antagonist. Theriogenology 1997;47:467–80.
[6.4] Brendemuehl JP, Cross DL. Influence of the dopamine antagonist domperidone on the
vernal transition in seasonally anoestrous mares. J Reprod Fertil 2000;(Suppl 56):185–93.
[6.5] Mari G, Morganti M, Merlo B, Castagnetti C, Parmeggiani F, Govoni N, Galeati G,
Tamanini C. Administration of sulpiride or domperidone for advancing the first ovulation in
deep anestrous mares. Theriogenology 2009;71:959-65.
98

[6.6] Kelley KK, Thompson DL , Storer WA, Mitcham PB, Gilley RM, Burns PJ. Estradiol
interactions with dopamine antagonists in mares: Prolactin secretion and reproductive traits. J
Equine Vet Sci 2006;26:517-28.
[6.7] Mitcham PB, Thompson DL, Burns PJ, Gilley RM. Recent advances in the use of an
estradiol-dopamine antagonist protocol to induce ovulation in seasonally anovulatory mares. J
Equine Vet Sci 2014;34:105-6.
[6.8] Mitcham PB, Thompson DL, Thompson TT, Bennett SD, Burns PJ, Caltabilota TJ.
Stimulation of ovulation in seasonally anovulatory and vernal transitional mares with estradiol
and domperidone: Dose and combination studies. J Equine Vet Sci 2010;30:244-8.
[6.9] Mitcham PB, Thompson DL, Burns PJ, Gilley RM, Hebert RC. Development of an
estradiol-dopamine antagonist protocol for inducing ovulation in seasonally anovulatory mares. J
Equine Vet Sci 2013;33:375-6.
[6.10] Mitcham PB. Development of an estradiol-dopamine antagonist protocol for inducing
ovulation in seasonally anovulatory mares. PhD dissertation. Baton Rouge: Louisiana State
Univ; 2012.
[6.11] Oberhaus EL, Thompson DL, Pham CK. Factors affecting the ovarian response to a
combined estradiol-sulpiride treatment in seasonally anovulatory mares. J Equine Vet Sci
2017;50:129-38.
[6.12] Oberhaus EL, Jones KL, King SS. Immunohistochemical localization of prolactin
receptors within the equine ovary. J Equine Vet Sci 2015;35:7-12.
[6.13] King SS, Jones KL, Dille EA, Roser JF. Prolactin receptors in the corpus luteum of
mares. Brazil: Porto Seguro: Proc 15th Int Congress Anim Reprod; 2004. Abstr 39.
[6.14] Clarke DL, Arey BJ, Linzer DI. Prolactin receptor messenger ribonucleic acid expression
in the ovary during the rat estrous cycle. Endocrinol 1993;133:2594–603.
[6.15] Clarke DL, Linzer DI. Changes in prolactin receptor expression during pregnancy in the
mouse ovary. Endocrinol 1993;133:224-32.
[6.16] Richards JS, Williams JJ. Luteal cell receptor for prolactin and luteinizing hormone:
Regulation by LH and PRL. Endocrinol 1976;119:1571-81.
[6.17] Holt JA, Richards JS, Rees Midgley A, Reichert LE. Effect of prolactin on LH receptor
in rat luteal cells. Endocrinol 1976;98:1005-13.
[6.18] Bjurulf, E., G. Selstam and J.I. Olofsson. Increased LH receptor mRNA and extended
corpus luteum function induced by prolactin and indomethacin treatment in vivo in
hysterectomized pseudopregnant rats. J Repro Fert 1994;102:139-45.
99

[6.19] Grosdemouge I, Bachelot A, Lucas A, Baran N, Kelly PA, Binart N. Effects of deletion
of the prolactin receptor on ovarian gene expression. Reprod Biol Endocrinol 2003;1:12.
[6.20] Bex FJ, Bartke A. Testicular LH binding in the hamster: Modification by photoperiod
and prolactin 1. Endocrinol 1977;100:1223-6.
[6.21] Bex F, Bartke A, Goldman BD, Dalterio S. Prolactin, growth hormone, luteinizing
hormone receptors, and seasonal changes in testicular activity in the golden hamster. Endocrinol
1978;103:2069-80.
[6.22] Amador A, Klemcke HG, Bartke A, Soares MJ, Siler-Khodr TM, Talamantes F. Effects
of different numbers of ectopic pituitary transplants on regulation of testicular LH/hCG and
prolactin receptors in the hamster (Mesocricetus auratus). J Reprod Fertil 1985;73:483-9.
[6.23] Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score,
physical measurements and body fat percentage for mares. Equine Vet J 1983;15:371-6.
[6.24] Thompson DL, Oberhaus EL, Ferreira JC, Arana Valencia N. Prolactin secretion in
estrogen-primed geldings: Effect of dose and site of injection of sulpiride in a vegetable
shortening vehicle. J Equine Vet Sci 2015;35:443-4.
[6.25] Thompson DL Jr, Godke RA, Squires EL. Testosterone effects on mares during
synchronization with altrenogest: FSH, LH, estrous duration and pregnancy rate. J Anim Sci
1983;56:678–86.
[6.26] Thompson DL Jr, Reville SI, Walker MP, Derrick DJ, Papkoff H. Testosterone
administration to mares during estrus: Duration of estrus and diestrus and concentrations of LH
and FSH in plasma. J Anim Sci 1983; 56:911-8.
[6.27] Colborn DR, Thompson DL Jr, Roth TL, Capehart JS, White KL. Responses of cortisol
and prolactin to sexual excitement and stress in stallions and geldings. J Anim Sci 1991;69:255662.
[6.28] Cartmill JA, Thompson DL, Storer WA, Gentry LR, Huff NK. Endocrine responses in
mares and geldings with high body condition scores grouped by high vs. low resting leptin
concentrations. J Anim Sci 2003:81;2311-21.
[6.29] Sticker LS, Thompson DL, Fernandez JM, Bunting LD, DePew CL. Dietary protein
and/or energy restriction in mares: Plasma growth hormone, IGF-I, cortisol, and thyroid hormone
responses to feeding, glucose, and epinephrine. J Anim Sci 1995:73;1424–32.
[6.30] Dell'Aquila ME, Caillaud M, Maritato F, Martoriati A, Gérard N, Aiudi G, Minoia P,
Goudet G. Cumulus expansion, nuclear maturation and connexin 43, cyclooxygenase-2 and FSH
receptor mRNA expression in equine cumulus-oocyte complexes cultured in vitro in the presence
of FSH and precursors for hyaluronic acid synthesis. Reprod Biol Endocrinol 2004;2:44.
100

[6.31] King SS, Jones KL, Mullenix BA, Heath DT. Seasonal relationships between dopamine
D1 and D2 receptor and equine FSH receptor mRNA in equine ovarian epithelium. Anim Reprod
Sci 2008;108:259-66.
[6.32] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time
quantitative PCR and the 2− ΔΔCT method. Methods 2001;25:402-8.
[6.33] Steel RGD, Torrie JH, Dickey DA. Principles and procedures of statistics: a biometrical
approach. 3rd ed. New York: McGraw-Hill; 1997.
[6.34] King SS, Roser JF, Jones KL. Follicular fluid prolactin and the periovulatory prolactin
surge in the mare. J Equine Vet Sci 2008;28:468-72.
[6.35] Watson ED, Thomassen R, Steele M, Heald M, Leask R, Groome NP, Riley SC.
Concentrations of inhibin, progesterone and oestradiol in fluid from dominant and subordinate
follicles from mares during spring transition and the breeding season. Anim Reprod Sci
2002;74:55-67.
[6.36] Donadeu FX, Watson ED. Seasonal changes in ovarian activity: lessons learnt from the
horse. Anim Reprod Sci 2007;100:225-42.
[6.37] Beg MA, Ginther OJ. Follicle selection in cattle and horses: Role of intrafollicular
factors. Reproduction 2006;132:365–77.
[6.38] Ginther OJ, Gastal EL, Gastal MO, Beg MA. Critical role of insulin-like growth factor
system in follicle selection and dominance in mares. Biol Reprod 2004;70:1374–9.
[6.39] Spicer LJ, Santiago CA, Davidson TR, Bridges TS, Chamberlain CS. Follicular fluid
concentrations of free insulin-like growth factor (IGF)-I during follicular development in mares.
Domest Anim Endocrinol 2005;29:573-81.
[6.40] Sessions-Bresnahan DR, Carnevale EM. The effect of equine metabolic syndrome on the
ovarian follicular environment. J Anim Sci 2014;92:1485-94.
[6.41] Hinrichs K, Rand WM, Palmer E. Effect of aspiration of the preovulatory follicle on
luteinization, corpus luteum function, and peripheral plasma gonadotropin concentrations in the
mare. Biol Reprod 1991;44:292-8.
[6.42] Mozzaquatro FD, Verstegen JP, Douglas RH, Troedsson MH, DeLaCorte FD, Silva CA,
Rubin MI. Progesterone production in mares and echographic evaluation of the corpora lutea
formed after follicular aspiration. Reprod Domest Anim 2012;47:288-92.
[6.43] Sharp DC. Vernal Transition. In: Equine Reproduction. AO McKinnon, EL Squires, WE
Vaala, DD Varner, eds. 2011; Chapter 178:1704-1715. Blackwell Publishing, Ltd, Hoboken, NJ.

101

OVERALL SUMMARY AND CONCLUSIONS
A series of experiments was performed to study the possible role for prolactin in the
seasonal recrudescence of ovarian activity in the mare in winter. The first experiment (Chapter
3) was based on cabergoline administration to seasonally anovulatory mares to prevent the
natural seasonal rise in endogenous plasma prolactin concentrations to assess whether reduced
prolactin altered the onset of ovarian activity or the timing of the first ovulation. Although
prolactin concentrations were altered in the early spring, basal prolactin concentrations
apparently recovered from cabergoline suppression by the time of the next injection (10 days
later), even though low-dose sulpiride stimulation of prolactin secretion was still suppressed by
85%. The subsequent experiment (Chapter 4) tested whether season affected the duration and
degree of suppression produced by a standard dose of cabergoline. Mares were administered an
injection of 1.5 mg/ 500 kg body weight of cabergoline in March, June, September, and
December. Duration of suppression was not affected by month of assessment. Follow-up
assessments with either low dose sulpiride (July) or TRH (October) challenges after
administration of 5 mg cabergoline indicated that basal prolactin concentrations always
rebounded faster (earlier) than secretagogue-induced secretion. The possibility of more than one
lactotrope population with differing sensitivities to dopaminergic suppression is discussed.
The third experiment (Chapter 5) studied the possible physical and hormonal
characteristics of seasonally anovulatory mares that might affect their response to a combined
estradiol and sulpiride treatment for inducing ovarian activity and ovulation in winter. Mares
from two farms were used. All mares received 50 mg of ECP followed by 3 g of sulpiride either
1 or 6 days later. Factors that were commonly associated with success (ovulation within 28 days)
were adequate body condition, elevated plasma concentrations of leptin and insulin, and a greater
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LH response to GnRH prior to the start of the experiment. Pregnancies were also produced in
75% of mares bred. It was concluded that, assuming a good prolactin response, factors associated
with good nutrition seem to be most important to the positive ovarian response.
Finally, Experiment 4 (Chapter 6) studied the hormonal production and secretory aspects
of the first pre-ovulatory (35 mm) follicle of the breeding season in seasonally anovulatory mares
treated with either 50 mg ECP followed by 2 injections of 3 g sulpiride 5 and 12 days later, or 50
mg ECP followed by 2 injections of vehicle only 5 and 12 days later beginning in January. Date
to first pre-ovulatory follicle was advanced in sulpiride-treated mares. Through assessment of
follicular hormone production and LH receptor mRNA, it was concluded that early-induced
follicles are equally as competent in terms of steroid production and ability to respond to
circulating LH as pre-ovulatory follicles occurring naturally in spring.
These experiments support the hypothesis that an increase in circulating prolactin during
seasonal anestrus can hasten follicular growth and advance the date to first ovulation in most
mares. Failure to observe any perturbations on vernal transition by incomplete suppression of
prolactin does not negate the decades of research which have detailed stimulatory effects of
prolactin on follicular growth. And while a prolactin response to dopamine antagonists is
necessary for early induced ovulation, magnitude of response is not an indicator of ovarian
success (assuming the response is above some theoretical threshold). Other factors, such as
nutrition and depth of anestrus, may mediate the ovarian response to the prolactin, whether it be
naturally occurring or induced by estradiol and sulpiride.
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APPENDIX: COPYRIGHT RELEASES FROM JOURNAL OF EQUINE VETERINARY
SCIENCE FOR CHAPTERS 3 AND 5
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